






Development of Drug-Eluting 
Surgical Sutures for the Wound-










A thesis submitted for the degree of  
Master of Science 











Incorporation of an anti-inflammatory drug with polymer materials to produce suture 
products is important especially when the suture is used for internal organs and/or 
tissues. In this work, poly(ε-caprolactone) (PCL), polyethylene glycol 400 (PEG400), 
chitosan and keratin were used as biopolymer matrix to encapsulate 5, 15, 30 wt% 
diclofenac potassium (DP) to achieve controlled drug release.  
At first, polymer alone was extruded by hot- melt extrusion technique under various 
temperatures and at different PCL/PEG400/chitosan-keratin ratios. The products were 
analysed in terms of FTIR characterization, thermal properties and mechanical 
properties. According to the characterization analysis of polymer sutures, the optimal 
polymer formulation (PCL: PEG400: chitosan/keratin= 80:19:1 wt%) (Group 1) was 
chosen to manufacture sutures with drug DP content at 5, 15, 30 wt%. In addition, 
PCL/PEG400/chitosan (Group 2) and PCL/PEG400/keratin (Group 3) were also 
fabricated with drug DP to create sutures, the polymer and drug weight ratios were 95:5, 
85:15 and 70:30 wt%. Drug release features were investigated via the drug dissolution 
test. MTT assay, live/dead assay and scratch assay were also applied to study the 
biocompatibility of drug embedded sutures.  
Results showed that sutures can be extruded with a smooth surface and uniform 
thickness under temperature of 63 ± 1 °C. It was observed from DSC and TGA studies 
that completely amorphous and miscible solid dispersions were prepared. FTIR 
analysis indicated that the presence of hydrogen bonds between the polymers improved 
material miscibility. Tensile properties of the sutures were clearly affected by PEG400, 
chitosan and keratin addition. The optimal formulation of tensile strength was obtained 
when PEG400: chitosan/keratin was 19:1 wt%.  Rapid drug release rate was observed 
at different stages of group 1, 2, 3. For group 1, the release occurred rapidly occurred 
after 1 h 45 mins, whereas group 2 exhibited fast release between 1 h 45 mins and 3 h 
45 mins. Group 3 displayed a sustained release where a fast release occurred from the 
onset to 3 h 45 mins. However, the final concentration of drug release in group 1 was 
lower than the other two groups, which can be predicted that a longer drug release time 
would be in an extended period compared to the other two groups. According to 




sample F3, which contained 30 wt% drug, and the ratio of PCL/PEG/chitosan-keratin 
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Surgical sutures are medical devices used for wound closure to hold body tissue together. 
Implanting sutures inside the human body may lead to an inflammatory response and/or 
postoperative surgical site infection (SSI), resulting in additional requirements such as 
pharmaceutical treatments. For example, oral administration of drugs often requires a high 
dosage due to low drug bioavailability and lack of specificity. Moreover, non-specific drug 
administration may have side-effects on tissues and organs that may or may not be the goal 
of the proper treatment. In this case, local drug delivery is essential (Champeau et al. 2017).  
Conjugating polymers with bioactive agents can achieve the purpose of controlling release 
kinetics and improving the targeting efficacy. Controlled release systems help to ensure a 
high drug concentration in the wound area (Lee et al. 2017). The utility of biodegradable 
sutures to deliver drugs not only eliminates the need of implanting foreign material inside the 
wound sites, but also effectively reduces surgical infection (Joseph et al. 2017). Sutures can 
be incorporated with an active pharmaceutical ingredient (API) , which is the component of 
any drug that produces the intended effects, to achieve controlled and optimal drug release at 
the wound site (Champeau et al. 2017).  
1.1 Antimicrobial Sutures 
Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) are the most popular 
organisms used in the trialling of new suture applications (Henry-Stanley et al. 2010). S. 
aureus, a class of gram-positive bacteria, may colonize the surface of implants. E. coli is a 
gram-negative organism, and is capable of triggering wound infections (Augustine and 
Rajarathinam 2012). Both organisms may cause complications in terms of wound healing 
when the suture is implanted inside the human body (Viju and Thilagavathi 2013b, Dennis et 
al. 2016). The hydrophobic or hydrophilic property of sutures determines the bacterial 
attachment preference. Most pathogens tend to attach to hydrophobic surfaces and have more 
stable viability under less humid environments (Ercan et al. 2018). However, Dhom et al. 




highest bacterial colonization, which was ascribed to its macrostructure. Thus, the 
macrostructure enabled the bacteria-containing liquid to be absorbed into the suture strand, 
which made cleaning difficult, leading to massive pathogenic growth (Dhom et al. 2017).  
Any artificial suture surface is prone to the attachment of microbial cells. Under moist 
conditions, these cells may attach and proliferate very quickly leading to the formation of a 
biofilm. This biofilm enables microbial cells to survive in a harsh environment, subsequently 
reducing susceptibility to antibiotics. In this situation, the suture material and wound site are 
both contaminated because of the formation of the biofilm (Joseph et al. 2017). The 
prevention of biofilm formation requires a suture with a biphasic release profile. This suture 
has a fast-antimicrobial release phase in order to retard biofilm formation initially, followed 
by a slow, prolonged release for maintaining a sufficient antibiotic concentration (Alvarez-
Paino, Munoz-Bonilla, and Fernandez-Garcia 2017). 
There are two common methods to combine API with suture materials. The first one is adding 
API during the suture manufacturing stage; the second is post-addition of API into ready-
made sutures (Champeau et al. 2017). The first method can be achieved by two fabrication 
processes: electrospinning and hot- melt extrusion. In these two processes, API is dispersed 
within the suture materials. The post-addition method can be achieved with process of dip-
coating or soaking (Champeau et al. 2017). Among them, the dip-coating method is the most 
prevalent strategy which involves coating the suture in a prepared drug solution. The suture 
simply absorbs the drug onto the surface, which leads to low drug loading and drug release 
efficiency (Lee et al. 2017). However, coating APIs on the suture surfaces results in rapid 
drug release (Champeau et al. 2017). Thus, blending APIs with suture materials during 
fabrication, such as hot- melt extrusion method, is more desirable when sustained drug release 
is required.  
The most important surgical suture characteristics for enhancing wound healing include: 
tensile strength, knot security, tissue reactivity and handling properties (Chu et al. 1996). The 
handling properties include pliability (i.e. structural flexibility) and friction force (i.e. the 
slipperiness of a suture during operation). Higher friction force may cause stronger tissue 
drag, and in extreme cases may lead to the difficulty of passing a suture through tissues, 




Additional antimicrobial agents may be used for repression of surgical site infections (SSIs). 
There are two main antibacterial strategies for using sutures. The first strategy uses cationic 
biopolymers to passively coat the suture surfaces to prevent bacterial attachment (Serrano et 
al. 2015). The second strategy incorporates APIs, such as silver or antibiotics, alongside 
suture materials, which releases API from the surgical suture after implantation within the 
human body (Serrano et al. 2015). This method of drug release is also called drug-eluting 
and is used for removing bacteria suspended in/around tissues and organs. While the former 
strategy offers the benefit of biocompatibility, the latter strategy is more effective. 
Drug-eluting sutures have been developed using a variety of fabrication methods, such as 
dip-coating, melt extrusion and electrospinning (Dennis et al. 2016). Figure 1 summarises 
the current manufacturing processes of drug-eluting sutures. Drug-eluting suture 
development has several problems, such as low tensile strength, maintenance of drug release 
rate, and commercial applications (Arora et al. 2019). Poly(lactic acid) (PLLA), Polyethylene 
glycol (PEG), and model drug levofloxacin (LVFX) have been applied to fabrication sutures 
with wet electrospinning technique. Formulations were increased with PEG content from 1% 
to 4%, which showed an initial burst release followed by a sustained release. However, the 
suture with the highest concentration of PEG had the largest bacteria-killing potential at 24 
hours (Kashiwabuchi et al. 2017). Therefore, the design of polymer-drug formulation is very 
important in terms of bacterial exhibition. The application of PEG as suture material was also 
investigated its impact on suture tensile strength. However, the varying concentrations of 
PEG did not attribute any significant effect to LVFX and PLLA (Dhom et al. 2017). To be 
able to tune the mechanical properties of sutures by adjusting formulations, chitosan, keratin 
and cellulose, or a selected combination of either two of them can be considered as addition 





Figure 1. Manufacturing Procedure of Drug-Eluting Sutures 
1.2 Classification of Suture Material  
Suture materials that include absorbable and non-absorbable sutures may both be classified 
as synthetic or natural sutures (Figure 2). The summary of suture materials is shown in Table 
1. Natural nonabsorbable materials such as cotton, silk and linen are less preferred since they 
are prone to SSIs. However, synthetic absorbable sutures have predictable degradation and 
relatively lower contamination potential (Lee et al. 2017). Thus, incorporating drugs with 






Table 1. General Comparison of Suture Materials and Properties  
Suture 
material 





Collagen Natural Absorbable Twisted  Low High 
Silk Natural Non-
absorbable 
Braided  Low High 
Line Natural Non-
absorbable 
Twisted  High High 
Cotton Natural Non-
absorbable 
Twisted  Low High 
Polydioxanone Synthetic Absorbable Monofilament High  Low 
Polyglyconate Synthetic  Absorbable Monofilament Moderate  Low 
Poliglecaprone Synthetic Absorbable Monofilament Low Low 
Polyglycolic 
acid 





Synthetic Absorbable Braided Moderate Low 
Polyester Synthetic Non-
absorbable 





Moderate  Low 
Polypropylene Synthetic Non-
absorbable 
Monofilament Moderate  Low 
Polybutester Synthetic Non-
absorbable 
Monofilament High Low 











1.2.1 Absorbable Sutures 
Absorbable sutures are defined as those that lose 50% tensile strength within 60 days of their 
application (Dennis et al. 2016). The reduction of tensile strength is attributed to proteolytic 
or hydrolytic degradation, depending on the natural or synthetic absorbable sutures (Erçin 
and Karahan 2018). 
Polymer sutures are effective when used in surgical applications if they meet the exacting 
needs of mechanical properties and the degradation rate. Claude et al. (2007) used rat models 
to study vascular anastomose using microsurgery. Even though there were no significant 
differences in macroscopic, histologic and functional assessments between absorbable and 
nonabsorbable sutures, the local tissue inflammatory reaction was more serious when 
nonabsorbable sutures were used in rat tissues (Claude et al. 2007).  
1.2.1.1 Natural Absorbable Suture Material  
Natural absorbable suture materials include catgut, which is derived from sheep or goat 
intestines and contains over 99% pure collagen. There are two catgut forms sold 
commercially; plain catgut and treated catgut tanned by chromium trioxide (called chromic 
catgut) (Pillai and Sharma 2010). Chromic catgut has stronger mechanical properties, a lower 
degradation rate than plain catgut, and may also reduce tissue reactions (Gabel et al. 2000). 
Catgut sutures are slowly degraded by proteolytic enzymes within the human body. The peak 
tensile strength of catgut sutures occurs <4 days post implantation, and completely loses 
tensile strength after 2 weeks (Pillai and Sharma 2010). Catgut suture are known to produce 
a strong inflammatory reaction the first three days after implantation (Bichon, Borloz, and 
Cassano-Zoppi 1984). Moreover, the absorption rate of catgut sutures is slower than the 
suture degradation rate (Chellamani, Veerasubramanian, and Balaji 2013), causing 
mechanical strength loss faster than wound healing, leading to complications (Tajirian and 
Goldberg 2010).   
Regenerated collagen (RC) has been reported to have low immunologic activity. Specifically, 
RC sutures made from bovine long flexor tendons have been exclusively utilised in 
microsurgery applications. RC may be produced by two methods; enzymatic digestion of 




2010). RC may be enhanced by making it spinnable, including crosslinking, grafting and 
blending (Krishnamoorthy et al. 2014, Hirano et al. 2000). Additionally, the mechanical and 
thermal properties of RC filaments may be improved by maturation during the incubation 
process (Pillai and Sharma 2010). For example, a study prepared RC from cattle skin through 
wet-spinning method, showing that the spun fibres had excellent biocompatibility with 
improved cell adhesion and proliferation (Wang et al. 2016).  
1.2.1.2 Synthetic Absorbable Suture Material  
Poly(p-dioxanone) (PDS) is a monofilament suture that has been recently developed due to 
its potential for excellent tensile strength and knot properties. It also demonstrates low tissue 
reactivity and enhanced hydrolysis. When PDS was used in x and y, the tissue reactivity was 
significantly lower than when x and y sutures were used. However, its melting point is low 
which may cause pyrolysis during spinning manufacturing process (Lee et al. 2014). 
Compared with poly(glycolic-co-lactic acid) (Vicryl®) and poly(glycolic acid) (Dexon®), 
PDS exhibits lower inflammatory reaction rates (Middleton and Tipton 1998). Commercially 
available PDS is sold in monofilament form, such as PDS®II and PDM ®. This suture may 
maintain > 50% of tensile strength after 4 weeks of implantation (Im et al. 2007). 
Additionally, PDS is also manufactured as a commercially available barbed suture product. 
For instance, Quill™ SRS is a bidirectional barded suture product used to close deep 
subcuticular layers and to close tissues in deeper layers, such as abdominal closures and 
paediatric cardiac procedures (Greenberg 2010).  
Polyglyconate sutures are commercial monofilament products fibres without coating 
(Maxon®). This suture, consisting of glycolic acid and trimethylene carbonate (1,3-dioxan-2-
one) building blocks, is sterilized by ethylene oxide (Chu 2013), which has been found to 
effectively reduces the body’s inflammatory response to suture application using this product. 
Moreover, Polyglyconate degrades via hydrolysis ~60 days after implantation inside the 
body. The degradation process continues for up to 180 days after implantation. This suture 
generates the best knot security compared to the other synthetic absorbable sutures and has 
been successfully used for soft tissues or ligation, including cardiovascular tissue and 




Poliglecaprone sutures, more commonly known as Monocryl®, are absorbable, monofilament 
sutures comprised of glycolide and epsilon caprolactone copolymers (PGCL) (Langley-
Hobbs 2013). This type of suture typically loses 50% of its tensile strength within 7 days after 
implantation and 100% tensile strength loss within three weeks. Therefore, it is only used for 
wounds with fast healing (Chu 2013). However, it has good knot security and handling 
properties attributed to its reduced pliability and poor structural memory (Chellamani, 
Veerasubramanian, and Balaji 2013). Moreover, it has been reported that Poliglecaprone has 
significantly lower microbial adherence rate than nonabsorbable multifilament and 
monofilament sutures (Chu 2013). Previous studies found that using monofilament 
Poliglecaprone sutures for wound healing caused less hypertrophic scar formation compared 
to multifilament Vicryl RapideTM. Even though absorbable sutures aren’t normally used for 
superficial wound healing, Poliglecaprone has been recommended for healing injuries to the 
face, ear, abdomen etc, as it provides great healing properties (Trott 2012). 
Poly(glycolic acid) (PGA), is the simplest biodegradable linear aliphatic polyester, and comes 
in monofilament, braided or coated forms. These sutures are widely used to treat 
contaminated wounds (Hochberg, Meyer, and Marion 2009). The only mode of degradation 
is hydrolysis, which comprises of two steps; i) firstly, ester bonds are hydrolysed by the water, 
allowing water to diffuses into the amorphous regions, ii) secondly, the entire polymer 
structure dissolves by the scission of the crystalline section (Pillai and Sharma 2010). After 
implantation in the human body, hydrolytic enzymes begin the degradation of PGA.  
Enzymes involved in the degradation of PGA include esterase, trypsin, and chymotrypsin 
(Makino, Arakawa, and Kondo 1985). The degradation products of PGA are non-toxic and 
are expelled by the body via urine (Pillai and Sharma 2010). Moreover, once implanted, 
PGA’s tensile strength is reduced by up to 80% in 14 days and alkaline conditions further 
decrease knot pulling strength (Chellamani, Veerasubramanian, and Balaji 2013). Further 
studies are warranted to explore the incorporation of monofilament PGA sutures with APIs 
to achieve a more controlled degradation and to reduce site infections near sutures (Lee et al. 
2014).  
Polyglactin 910, also known as Vicryl®, is a braided suture that consists of copolymers of 
glycolic acid and lactic acid in a 90/10 mol/mol multifilament form. This suture is coated 




implantation, followed by gradual degradation between 100 to 120 days. Many researchers 
have employed coating techniques to cover Polyglactin 910 with bioactive agents, resulting 
in less tissue drag and a lower rate of wound infection (Chellamani, Veerasubramanian, and 
Balaji 2013). Vicryl® rapid is a Polyglactin 910 variant with improved degradation rate 
compared to Vicryl®. Panacryl® is another variant formed by the copolymer of glycolic acid 
and lactic acid but with higher ratios of these two acids, which reduces the rate of suture 
degradation inside the human body (Pillai and Sharma 2010).  
1.2.2 Non-Absorbable Sutures 
Non-absorbable sutures consist of non-biodegradable biomaterials, such as silk, nylon, 
polyester and metal. They are more mechanically durable than absorbable sutures. The 
application of non-absorbable sutures is limited to skin, fascia or tendons where tissues 
require higher tensile strength (Lee et al. 2017). Despite the excellent mechanical properties 
of non-absorbable sutures provide to wound sites. The major disadvantage of using non-
absorbable sutures is that they are required a second procedure to remove the sutures after 
the wound heals (Joseph et al. 2017). 
1.2.2.1 Natural Non-Absorbable Sutures 
The braided form of silk is used as a natural nonabsorbable surgical suture material. It is dyed 
black for better visibility and is usually coated with oil, wax or silicone for improved 
toughness. Despite enhancements, silk sutures have the lowest tensile strength compared to 
all the currently available sutures (Hochberg, Meyer, and Marion 2009). Additionally, studies 
have shown that the braided sutures using silk material may introduce pathogens into the 
wound site, leading to infection (Wu et al. 2016). However, silk sutures show a high 
performance in serum and have good water-repellent properties. Silk sutures are mainly used 
to reduce inflammation once placed in the wound site and are not responsible for anti-
bacterial action (Chellamani, Veerasubramanian, and Balaji 2013). 
Linen sutures are most commonly produced in the twisted multifilament form flax (Fong et 
al. 2015), and they may also be coated with silicone and polyvinyl solutions (Chellamani, 




and have the ability to gain 10-20 % tensile strength in an aqueous environment due to their 
non-absorbable property, suggesting that a wet linen suture is able to endure high stress while 
securing wound closure (Cherif et al. 2013). 
Cotton, extracted from cotton plants, is coated with wax to be used for surgical suture 
applications. A cotton suture typically loses 50% tensile strength within half a year and can 
completely lose strength within two years (Ratner et al. 2004). Like linen sutures, cotton 
sutures may gain roughly 10% tensile strength when moist. Wound site infections and tissue 
reactions may occur frequently using cotton suture due to its high capillarity (Chellamani, 
Veerasubramanian, and Balaji 2013). In addition, cotton suture material can generate static 
electricity causing it to cling to surgical linen (Ratner et al. 2004). Therefore, the application 
of cotton sutures is limited.  
1.2.2.2 Synthetic Non-Absorbable Sutures  
Polyester sutures are nonabsorbable multifilament braided structures comprised of 
polyethylene terephthalate. These sutures are commonly utilized in the coated form as it adds 
variation to their application. Various coatings, such as polybutylate, Teflon and silicone may 
reduce tissue drag (Chellamani, Veerasubramanian, and Balaji 2013). These types of sutures 
have extremely high tensile strength, ranking only lower than metal, and very little to no loss 
in tensile strength observed after implantation (Herrmann 1971). Furthermore, these sutures 
provide sustained support for slowly healing tissues and produce minimal tissue reactivity 
(Hochberg, Meyer, and Marion 2009). These are generally used for soft tissues such as 
cardiovascular and ophthalmic applications. 
Polyamide was the first developed synthetic suture. It can be applied in both monofilament 
and multifilament forms, giving it flexibility in possible applications. The multifilament form 
of polyamide sutures is commonly used in dermatologic surgery. However, even though it 
demonstrates excellent handling properties during operation, the tissue reactions are 
frequently observed (Debbabi and Abdessalem 2015). When in monofilament form, the 
widely used polyamide suture, Nylon, may lose 30 % of tensile strength within two years 
after implementation, giving it excellent long-term degradation resistance. However, in 
multifilament form the entire tensile strength may degrade within six months (Chellamani, 




Polypropylene is available in the monofilament form and it is formed by catalytic 
polymerisation of propylene. It is the best suture for the skin healing process (Chellamani, 
Veerasubramanian, and Balaji 2013). As it is easy to implant and remove from the skin due 
to its naturally smooth surface. it may maintain the same tensile strength after implantation. 
And it is also able to pass through skin tissue and induce minimal inflammatory responses. 
However, the smooth surface may reduce knot security (Hochberg, Meyer, and Marion 2009).  
Polybutester is a monofilament suture that has thermoplastic properties and is composed of 
polybutylene, polyglycol and polytetramethylene terephthalates (Chellamani, 
Veerasubramanian, and Balaji 2013). Polybutester has sufficient tensile strength to support 
tissue healing processes (Hochberg, Meyer, and Marion 2009). It does not have significant 
suture memory and will not remain its shape in the package like nylon and polypropylene. 
Therefore, polybutester exhibits excellent handling properties and higher knot security. 
Moreover, polybutester sutures demonstrate lower chance of causing hypertrophic scarring 
than nylon sutures (Trott 2012).  
Stainless steel, the metallic suture that can be applied in both monofilament and multifilament 
structure. It has the highest tensile strength and knot security compared to the other available 
suture materials. It also maintains its tensile strength throughout the entire healing process. 
Moreover, it is easily sterilised using the autoclaving process. But it tends to cut tissues in 
the wound site, and knot tying is difficult to perform with stainless steel sutures (Chellamani, 
Veerasubramanian, and Balaji 2013).  
1.3 Sutures with Active Pharmaceutical Ingredients 
(APIs) 
Many researchers have worked on sutures incorporating APIs. Amongst them, some existing 
studies have developed fatty acid or silver nanoparticle coated silk sutures to ensure a slow-
release drug delivery system (Wu et al. 2016). Chen et al. (2015) coated the braided silk 
sutures by mixing levofloxacin hydrochloride and PCL and found excellent antimicrobial 




Chitosan is an ideal candidate to facilitate wound closure as it has excellent antimicrobial and 
scar preventive characteristics along with the low toxicity. The antimicrobial mechanism 
operates by binding positively charged amine groups with negatively charged microbial 
surfaces (Muzzarelli and Muzzarelli 2005), which affects cell permeability and leads to 
leaking of bacterial cell cytoplasm and apoptosis. Viju and Thilagavathi (Viju and 
Thilagavathi 2013b) studied the effect of varying concentrations of chitosan on the braided 
silk sutures, and they observed that the increase in chitosan concentrations resulted in knot 
strength improvement. Furthermore, agar diffusion experiments demonstrated that higher 
chitosan concentration inhibited both E. coli and S. aureus bacteria better than lower 
concentrations (Viju and Thilagavathi 2013b). Chitosan-collagen blends allow additional 
suture properties, such as allowing collagen to be spinnable. The hydrogen bond between 
chitosan and collagen modifies the triple helix structure of collagen and enable mixing at the 
molecular level (Chen et al. 2010). Optimal mechanical and biological properties may be 
achieved with chitosan-collagen blends of 4 to 1 collagen to chitosan (Wang et al. 2016).  
Reinbold et al. (2017) developed a novel hydrophobic, bioactive agent of totarol to act as an 
antibacterial coating agent on surgical sutures in order to reduce SSIs (Reinbold et al. 2017). 
Even though the results showed that the totarol coating inhibited bacterial biofilm formation 
compared to uncoated sutures, the inhibition zones of the agar diffusion test were generally 
small, attributed to the poor diffusion of totarol within the sutures (Reinbold et al. 2017). To 
improve the efficacy of totarol diffusion, other suture materials such as PCL, PLA and PGA 
may be considered as alternatives (Liu et al. 2020).  
Nitric oxide (NO) is a natural antibacterial agent found to facilitate wound healing. The 
gaseous delivery of NO to wound sites is not practical, as it is a diatomic free radical, making 
it reactive. A way to deliver NO in solid form would be ideal (Lowe et al. 2014). Solid 
delivery of NO to tissues is achieved by the incorporation of NO into a suture, which produces 
a thromboresistant antimicrobial material able to provide enhanced healing to both chronic 
and acute wounds (Lowe et al. 2014, Tummalapalli et al. 2016). Lowe et al. (Lowe et al. 
2014) utilized the melt spinning technique to control the release of NO. The suture was coated 
with PCL. The result showed that melt-spun sutures had high tensile strength, and PCL coated 
sutures significantly decreased NO release compared with the uncoated suture, which makes 




Triclosan is an antiseptic agent that has antibacterial and antifungal properties. It has been 
fabricated with several synthetic materials such as polydioxanone and polyglactin to produce 
absorbable sutures (Leaper et al. 2011, Leaper et al. 2017). Triclosan coated sutures offer 
high antimicrobial drug concentrations to SSIs, especially preventing the formation of 
biofilms. Microbial activity is retarded in the presence of triclosan due to its ability to inhibit 
bacterial fatty acid synthesis and reproduction (Leaper et al. 2017). Justinger et al. coated 
triclosan to Vicryl Plus® sutures and polydioxanone sutures respectively. The results showed 
that triclosan coated Vicryl Plus® sutures reduced wound infection significantly (Justinger et 
al. 2009). However, a study of 26 patients undergoing breast reduction surgery found that 
nine out of sixteen patients had dehiscence in triclosan-coated suture group (Deliaert et al. 
2009), which questions the effectiveness of the triclosan-coated materials in wound healing. 
However, since triclosan has been widely used in healthcare and cosmetic products, a high 
percentage of triclosan has been detected in the urine of US citizens (Han, Lim, and Hong 
2016), which may lead to gradual microbial resistance inside the human body (Carey et al. 
2016).  
Octenidine has been studied as an alternative API to triclosan. For example, octenidine coated 
PGA sutures, with fatty acid carriers, were tested for their antimicrobial efficacy on S. aureus. 
When compared with the triclosan control group (Vicryl Plus®), the inhibition zones observed 
were smaller on octenidine coated sutures than on the control group for up to nine days, which 
can be attributed to the lower solubility of octenidine, leading to slower drug release. An in 
vitro drug release study showed that octenidine coated sutures have a sustained release profile 
similar to triclosan coated sutures (Obermeier et al. 2018). It was also shown that octenidine 
coated sutures had no considerable effect on human metabolic activities and that they meet 
the ISO standard of biocompatibility through the cytotoxicity tests. Overall, the antimicrobial 
efficacy of octenidine coated sutures was only slightly lower than the commercial triclosan 
coated sutures, and the low toxicity of octenidine coated sutures makes them an ideal 
candidate for clinical applications (Obermeier et al. 2015).  
Obermeier et al. (2015) found that Chlorhexidine (CHX) and octenidine, in conjunction with 
only fatty acid carriers (palmitic and lauric acid), may be viable alternatives for triclosan 
(Obermeier et al. 2015). They have a broad antimicrobial spectrum and biocompatibility, 




antimicrobial mechanisms of these two active agents are similar, as both use positively 
charged API molecules that bind with negatively charged bacterial cells, resulting in microbe 
membrane leakages (Obermeier et al. 2015). Similarly, other research showed that the 
antimicrobial efficacy lasts for 9 days for octenidine coated sutures, and up to 5 days for CHX 
coated sutures (Obermeier et al. 2018). Researchers found that octenidine and chlorhexidine 
coatings had higher antimicrobial activity than commercial Vicryl Plus® across varying 
solubilities in aqueous solutions (Obermeier et al. 2018). In ascending order of solubility, 
triclosan had the lowest solubility, followed by octenidine and CHX. Additionally, CHX-
laurate sutures had very few viable adhered bacteria, even though incubation condition had 
higher bacterial concentration, which suggests excellent antimicrobial activity for CHX-
laurate (Obermeier et al. 2018). Authors recommended this type of suture as a supplement to 
Vicryl Plus® for future clinical applications. 
1.4 Suture Structure 
1.4.1 Monofilament and Multifilament (Braided) Sutures 
Monofilament sutures are single strands of fibres, whereas multifilament sutures consist of 
several strands braided together. Generally, multifilament sutures have good handling 
properties and create better knots than monofilament fibres, as monofilament sutures provide 
higher frictional force and have greater stiffness. Monofilament sutures have weaker knot 
strength and break more easily (Lee et al. 2014).  
Additionally, braided sutures have much higher capillarity than non-braided sutures, allowing 
fluid to pass through the suture thread (Joseph et al. 2017), The capillarity of braided sutures 
makes them more prone to tissue inflammation/ immune reaction than monofilament sutures, 
as fibre capillarity has been associated with a more suitable habitat for bacteria (Busse 2016, 
Joseph et al. 2017). Nevertheless, larger inhibition zones were observed when a multifilament 
suture was coated with APIs compared to the monofilament sutures (Reinbold et al. 2017), 
suggesting that capillarity plays a role in drug delivery/dosage. The twisted structure of 
braided sutures offers a larger surface area for the coating, and allows the APIs to be absorbed 




structural flexibility and provide greater surface area for coating than monofilament sutures, 
which makes multifilament sutures better for anti-microbial action. 
1.4.2 Barbed Sutures 
Barbed sutures (Figure 3), are bidirectional or one-directional/unidirectional surgical sutures 
without a knot. Unidirectional barbed sutures are made with monofilament fibres. The barbs 
on the suture body are unidirectional and the needles are swaged onto one end (Figure 3a). 
The opposite end is secured by an anchor or knot to prevent movement to the opposite 
direction where barbs are facing (Greenberg 2010). Similar to unidirectional sutures, 
bidirectional barbed sutures are also made from monofilament fibres. Barbs are formed by 
cutting the suture around the perimeter in a helical pattern. The two group of barbs face each 
other on two sides of the suture according to the midpoint (Figure 3b). The needles are swaged 
on two ends of the length for suture anchoring (Greenberg 2010).  
Barbed sutures have several advantages over traditional monofilament and multifilament 
sutures. For example, barbed structures allow for secure closure of multiple skin layers 
without knot tying, which enhances the tensile strength of the suture (Tummalapalli et al. 
2016). Moreover, barbed sutures retard bacterial attachment and growth, which reduces tissue 
inflammation and wound infection (Joseph et al. 2017). In a study, three types of the sutures 
(monofilament, multifilament and barbed sutures) were coated with an antibiotic substance 
and placed in a contaminated wound site. it was reported that the barbed suture had the highest 
bacterial inhibition (Dhom et al. 2017). Even though barbed sutures have advantages in 
clinical applications, the design of the barb front can accidentally puncture the surgical glove 
and result in the transference of infections to the surgeons and cause further wound site 
infections to the patients (Dennis et al. 2016). Furthermore, the cutting-type barbs may 
potentially weaken the suture core, thinning the suture diameter and reducing the tensile 
strength (Umranikar et al. 2017, Greenberg and Goldman 2013). However, with careful 
handling, barbed sutures may exert excellent antimicrobial activity in securing wound healing 






(a) One directional barbed suture 
 
(b) Bidirectional barbed suture 
 
Figure 3. Barbed Suture 
1.4.3 Smart Sutures 
Suture ‘smartness’ is a term used to describe the ability of the suture to return to the original 
shape once its shape has been altered. These sutures can be stretched at below critical 
temperatures before implanting. Firstly, the suture is applied loosely to the wound site, then, 
once the temperature rises either under body conditions or with the aid of external sources, 
the suture returns to its original shape. Smart sutures show good pliability and mechanical 
property for achieving self-tightening (Dennis et al. 2016). In terms of knot making, a tight 
knot may cause the damage of healthy cells, leading to skin necrosis. On the other hand, a 
loosely sealed wound line would introduce foreign substances to infiltrate wound site (Duarah 
et al. 2018). Therefore, a smart suture that can self-tighten under body temperature is desired. 
1.5 Fabrication Process 
There are three commonly used procedures in manufacturing surgical sutures; 
electrospinning, hot- melt extrusion and coating (Figure 1). Electrospinning and hot- melt 
extrusion allow APIs to disperse throughout the suture body in order to achieve the controlled 
release of drugs. The coating includes dip coating and layer-by-layer coating. Dip coating is 
the immersion of the surgical suture into the API solution. The layer-by-layer coating is a 
layer by layer deposition of APIs. In both cases, the drug is coated on the surface of the suture 




Table 2. The Summary of Drug-Eluting Suture Fabrication Processes 
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In the production of sutures, electrospinning is used to achieve porous nanofiber sutures. 
There are two types of electrospinning; uniaxial and coaxial electrospinning, which will be 
described below. An electrospinning device consists of a syringe, a high voltage emitter and 
a collector. The drug/polymer mixture is injected into the syringe and electrospun into 
nanofibers. This technique can fabricate suture materials into porous nanofibers with 
diameters from 5 to 500 nm (Champeau et al. 2017). The utilisation of a high electric field 
enables the formation of large surface areas (Champeau et al. 2017, Joseph et al. 2017). Even 
though the various advantages of electrospinning, electrospun nanofibers generally have poor 
mechanical performance, as they are in nonwoven form but generally, the thinner the fibre 
diameter, the higher the mechanical strength (Hu, Huang, and Liu 2010).  
In uniaxial electrospinning, the drug migrates to the surface of the fibre and forms high 
concentrations, as shown in Figure 4 (a). This is commonly seen when small hydrophilic 
molecules are applied to the matrix. Consequently, an ideal controlled drug release cannot be 
achieved, as a burst release appears in this circumstance. In coaxial electrospinning, the drug 
is encapsulated inside the core of the fibre and surrounded by a polymer-formed shell to 
generate a core-shell structure. To achieve this, the drug and the polymer are loaded in 
separate syringes and the drug solution is injected into the centre of the polymer loaded 
capillary, as shown in Figure 4(b). This approach is particularly useful for immiscible drugs, 
organic solvent-sensitive or electric discharge-sensitive drugs. However, once the drug starts 
eluting, the tensile strength of the fibre tends to decrease, which is a drawback for wounds 






Figure 4. (a) Uniaxial Electrospinning and (b) Coaxial Electrospinning  
He et al. (2009) applied both blend and coaxial electrospinning processes to study 
antimicrobial drug-eluting sutures with tetracycline hydrochloride (TCH) and PLLA. In the 
blend electrospinning process, drug and polymer were dissolved in hexafluoroisopropanol 
(HFIP). In the coaxial electrospinning process, TCH and PLLA were the core and the shell 
respectively, which formed the core-shell structure (Figure 5). While the release profile of 
the blend electrospun sutures showed an initial burst followed by a sustained release, the 
core-shell sutures operated a controlled release. Additionally, the presence of the drug in both 
blend and coaxial electrospinning had a negligible effect on the mechanical properties of 
sutures, suggesting that the drug formed molecular interactions with polymers (He, Huang, 
and Han 2009).   
 
Figure 5. Core-Sheath Structure 
Most of the heat-sensitive compounds cannot be utilised with the melt spinning technique 
because the procedure uses high temperatures. Padmakumar et al. (2016) thus used the 
electrospinning technique to manufacture drug-loaded sutures. This approach can enable 
stable drug loading and a controlled drug release rate. However, electrospun fibres often 
demonstrate low mechanical properties. The fibre strength may improve with post-processing 
at high-temperatures, but the integrity of heat-sensitive drugs may be altered under these 
harsh conditions (Padmakumar et al. 2016). To avoid this problem, Padmakumar et al. (2016) 
utilised a PLLA core, and the drug-loaded PLLA sheath was electrospun onto the core. With 
this method, they were able to reduce the core diameter, maintain the drug function, and 
enhance the mechanical strength of the fibre (Padmakumar et al. 2016). The same research 
group has developed an electrospinning technique to produce a slow, controlled drug release 
system. They showed that nanofibers would form in the yarn, which caused the drug 
molecules to interact with the large surface area of the inter-fibres tightly, therefore, achieving 




Lee et al. (2013) demonstrated a novel drug-eluting suture system consisting of a drug-
delivery sheet and a surgical suture. The sheet contained PLGA and was loaded with the drug 
Ibuprofen. The sheet was manufactured via electrospinning at a voltage of 15 kV, and was 
then physically braided and cured on the suture at 47°C. This system controls not only the 
drug delivery, but also maintains the mechanical strength. Moreover, tailoring the 
nanofibrous sheet is necessary for avoiding the impact on the mechanical strength of the 
suture and adjusting the drug release profile (Lee et al. 2013). 
1.5.2 Melt Extrusion  
Melt extrusion (Figure 6) is a widely applied technique that can manufacture monofilament 
sutures. This method has advantages compared to conventional preparation processes. For 
instance, the drug administration time can be reduced which then lowers the amount of drug 
usage for manufacturing (Li et al. 2013). Melt extrusion technique can disperse different API 
in a matrix at a molecular level, and can increase the solubility of poor water-soluble or 
hydrophobic compounds (Catanzano et al. 2014).  
 
Figure 6. Melt Extrusion Process 
Melt extrusion has wet and melt spinning. These techniques are simple to implement, and the 
APIs can be homogeneously distributed into the suture cross-section, achieving prolonged 
drug release (Tummalapalli et al. 2016). Moreover, where other techniques require solvents, 
this technique is solvent-free, which is more environmentally friendly and cheaper to 
produce. Besides, this one-step process may be scaled-up, making it easy to move from 
laboratory to commercial production. However, the drawback of this method is that often the 
increase in the drug content leads to the decrease in the mechanical properties of the suture. 




production. For instance, the filaments manufactured via melt-spun are usually without voids 
(Tummalapalli et al. 2016) However, it is generally accepted that high melting point 
polymers cannot be fabricated with thermolabile drugs (Champeau et al. 2017). Nevertheless, 
a previous study proposed that incorporating hydrotalcite-like compounds with APIs that 
have poor thermal stability can effectively maintain their physiochemical integrity 
(Catanzano et al. 2014). With this technique, melt extruding thermolabile drugs with 
polymers would become more common.  
Studies looking into drug release found that the intercalation of API molecules in lamellar 
hydrotalcite-like compounds may obtain sustained drug release profiles (Catanzano et al. 
2014, Perioli, Ambrogi, et al. 2011, Perioli, Posati, et al. 2011). For example, melt-spun PCL 
fibres which incorporated with diclofenac (Dic) were studied (Catanzano et al. 2014). In the 
Dic nanohybrid, the API was intercalated with a synthetic hydrotalcite to form hydrotalcite-
like compounds (HT-Dic). The result demonstrated that the mechanical property and the drug 
release profile of the sutures largely depend on the Dic-loaded form. Furthermore, the 
combination of both Dic and HT-Dic even allowed further adjustment of the drug release 
rate, a release profile beyond 70 days was achieved (Catanzano et al. 2014). This study 
suggests a possible production of a more advanced suture that can achieve a sustained release 
of anti-inflammatory drugs by using hydrotalcite-like compounds. 
The melt spinning technique was also used to fabricate PCL monofilaments incorporated with 
chlorhexidine diacetate (CHX) (topical anti-infective agent) (Scaffaro et al. 2013). Compared 
to PCL/HT-Dic loaded sutures, when the concentration of PCL/CHX was 4%, the sustained 
release of PCL/CHX sutures occurred for 6 days compared with the 70 days that PCL/HT-
Dic achieved. An interesting observation was that even though CHX in pure form showed 
toxicity to human fibroblast cells, the PCL/CHX compound exhibited excellent cell viability 
and low toxicity, suggesting that the interaction between the polymer and CHX inhibits the 
potential toxicity that CHX may have in live tissues (Scaffaro et al. 2013).  
The immunostimulant, Cytosine–phosphonothioate–guanine oligonucleotides (CpG ODN), 
was mixed and melt-extruded with polylactic acid-co-glycolic acid (PLGA). The collected 
sutures showed an intact structure in scanning electron microscopy images and reached 
diameters ranging from 50 to 300 μm. CpG ODN had a sustained release of up to 35 days. In 




utilized for wound closure compared to the application of polyglycolic Acid (Dexon®) 
sutures, polyglactin 910 (Vicryl®) sutures or a combination of both (Intra et al. 2011).   
The melt spinning method was employed to fabricate an acrylonitrile-co-1-vinylimidazole 
(AN/VIM) copolymer that incorporated nitric oxide (NO). In order to control the release rate 
of NO, the melt-spun monofilaments were dip-coated with poly(ɛ-caprolactone) (PCL) 
solution. The formed porous structure enables prolonged NO release from AN/VIM fibres up 
to 3 days, compared with 3 hours release of uncoated fibres (Lowe et al. 2014). As mentioned 
before, NO is effective as an anti-inflammatory coating. Thus, this method is able to apply 
NO to suture fabrication despite its limitations mentioned earlier.  
1.5.3 Coating  
The simplest approach to add API to a manufactured suture is coating suture surface with the 
desired drug (Champeau et al. 2017). It is relatively cheap and tensile strength of the suture 
is maintained. The drug release profile can be adjusted by controlling the property of the 
bioactive agent, such as its porosity, thickness and degradation rate. Coatings generally 
adhere to sutures through absorption, ionic interaction, and van der Waals forces. Those 
commercially available antimicrobial sutures such as Vicryl Plus®, PDS Plus® and Monocryl 
Plus® are all coated with triclosan. The property of triclosan produced sutures with smooth 
surfaces, which reduces tissue drag and immune reaction (Tummalapalli et al. 2016).  
The dip-coating method is the most prevalent strategy which involves coating the suture in a 
prepared drug solution. Another coating method has also received attention known as layer-
by-layer deposition. This coating method is similar as dip-coating, the difference is that the 
layer-by-layer method requires the suture to be dip-coated into the single API solution or 
multiple different API solutions for several times to achieve excellent antimicrobial effects 
(Dubas, Wacharanad, and Potiyaraj 2011). The suture simply absorbs the drug onto the 
surface, leading to sufficient drug loading and drug release efficiency (Lee et al. 2017). 
However, coating APIs on the suture surfaces may result in rapid drug release (Champeau et 
al. 2017). 
Matl et al. (2009) used the dip-coating method to coat Pollyglactin-910 sutures with a 
combination of CHX and octenidine with palmitic and lauric acid acting as a carrier. The 




based drug delivery system improved the surface smoothness and reduced the tissue drag 
during sewing, the experimental group demonstrated excellent antimicrobial activity, and the 
sustained drug release lasted long enough to achieve anti-infection. However, in vitro studies 
using L929 mouse fibroblasts showed that the cytocompatibility of modified sutures was 
inferior compared to Vicryl Plus® (Matl et al. 2009).  
Wang et al. (2009) applied the layer-by-layer deposition method. One example is that a silk 
fibre was coated with poly(allylamine hydrochloride) (PAH) and dextran, along with 
hyaloplasm acid (HA), layer by layer to develop an anti-inflammatory suture system. The 
mixture was then soaked into an Ibuprofen solution. It was found that the sustained drug 
release lasted for 10 days in 0.9% normal saline (Wang, Chen, and Sun 2009). Another 
example is that braided natural and synthetic sutures, such as silk, polyester and PLLA 
sutures, were coated with the incorporation of polyelectrolyte and CHX multilayer films. It 
was observed that sutures with CHX-functionalized films exhibited a significant impact on 
preventing bacterial colonisation. Interestingly, there was no bacterial attachment on sutures 
for up to 7 days (Harnet et al. 2009).  
There was a novel formulation proposed by Chen et al. (2015). They coated sutures with 
levofloxacin hydrochloride (LVFX-HCL) and poly (ɛ-caprolactone) (PCL) (Chen et al. 
2015). The coating process was composed of two-dipping and two-rolling steps, which 
controlled the thickness of the sutures. The experiment involved four different groups of 
sutures, such as coated shell and strands, coated braided yarns, uncoated braided silk sutures, 
and PCL-coated sutures without LVFX-HCL. The result demonstrated that all study groups 
had the antimicrobial properties, and the group of LVFX-HCL and PCL coated shell and 
strands showed higher potential for clinical applications (Chen et al. 2015). In the following 
study, the same research group investigated the effect of the number of coating repetitions on 
suture characteristics. They found that the increase of the number of repetitions led to the 
decrease of knot-pull tensile strength and the bending stiffness, which can be attributed to the 
thicker diameter (Chen et al. 2015). 
1.6 Conclusion  
Polymers play a vital role in medical applications. Their high flexibility gives surgical sutures 




received much attention, since they can be degraded inside the human body through 
proteolysis degradation or hydrolytic degradation without post-surgery extraction, which 
significantly reduces the chance of surgical infection and prolonged patient suffering.  
It is widely accepted that within the drug-eluting suture process, that adding API during 
manufacturing is the most ideal, because it is a one-step process and does not require much 
equipment, which can reduce cost and allow mass production.  
Melt extrusion processes should be employed whenever conditions are applicable. As it does 
not require a solvent removal step, and it meets environmentally friendly requirements. 
However, in some cases, a thermolabile API is required for the drug-eluting suture 
applications. The high temperature in the melt extrusion process would destroy the structure 
of the thermolabile drug. Thus, electrospinning is a better choice.  
Even though both melt extrusion and electrospinning can manufacture drug-eluting sutures 
with a drug content up to 20%, the higher drug amount leads to a lower tensile strength of the 
sutures. However, in some suture applications, high drug content is required. In order to 
maintain the tensile strength and meet the high drug amount requirement, coating can be 
applied.  
During the drug-eluting suture engineering, the tensile strength of the sutures has been widely 
studied. However, detailed mechanical properties during surgery such as knot-pulling 





2 THE CURRENT PROJECT 
2.1 Fabrication of Drug-Eluting Sutures with Hot- 
melt Extrusion Technique 
At present, there are no studies that have investigated the biopolymer blend of 
PCL/PEG400/chitosan/keratin for surgical suture applications, in particular, using diclofenac 
potassium, as the target drug. Brianezi et al. used PCL/PEG/chitosan to control the release 
rate of gentamicin for skin wound healing (Brianezi et al. 2018). This medical device 
demonstrated the ability of inhibiting the growth of E. coli and S. aureus. Another study 
extruded PLA/PCL blend with Ethyl Ester L-Lysine Triisocyanate. The results showed that 
the higher drug loads resulted in decreased suture ductility (Visco et al. 2019).  Usually for 
absorbable synthetic suture studies, researchers focus more on PLA-based sutures (He et al. 
2014, Tyler et al. 2016, da Silva et al. 2018, Liu et al. 2019). Furthermore, the recruitment of 
the hot- melt extrusion technique for surgical suture manufacturing has not obtained much 
attention (Catanzano et al. 2014). Most researchers focus on suture coating to achieve outer 
layer drug release (Baygar et al. 2019, Chen et al. 2015, Obermeier et al. 2015, Reinbold et 
al. 2017). However, using this coating technique, it is difficult to control the drug release rate, 
due to the simple attachment of the drug onto suture surfaces (Lee et al. 2017).  
This study was designed to explore the novel biomaterials of PCL, PEG400, chitosan and 
keratin mixed in various ratios with the anti-inflammatory drug diclofenac potassium. These 
were extruded using the hot- melt extrusion method. The hot- melt extruder was used for 
dissolving the biopolymers and the drug, creating an amorphous solid dispersion state, which 
ensured that the biopolymers and drug were mixed at a molecular level to achieve 
homogeneity. The high temperatures during the hot- melt extrusion may be seen as a 
limitation, as most drugs are not stable under high temperatures. Therefore, a low extruding 
temperature is essential. The most suitable biopolymer was PCL, due to its thermoplastic 
property with a low melting point and glass transition temperature (Dash and Konkimalla 




a more complex and robust absorbable surgical suture, which can also reduce the surgical site 
infection and inflammation.  
2.2 Materials Selected for This Study  
Poly(ɛ-caprolactone) (PCL) has been widely utilized in biomedical applications such as 
controlled release drug delivery systems and absorbable surgical sutures (Malikmammadov 
et al. 2018). It is a synthetic biodegradable polyester which with a molecular weight ranging 
from 3,000 to 80,000g/mol. This material has a low melting point of 59-64°C, and the glass 
transition temperature is 60°C (Dash and Konkimalla 2012a). PCL is an ideal candidate for 
melt processing, due to its biocompatibility and biodegradability (Malikmammadov et al. 
2018). It is also one of the biopolymers that has been approved to be used in the biomedical 
application by Food and Drug Administration (FDA) (Azimi et al. 2014).  
According to previous studies, PCL is compatible with a wide range of pharmaceutical 
ingredients, which allows drug distribution uniformly throughout the polymer matrix. 
Moreover, its long-term degradation property enables the drug release to last for several 
months (Dash and Konkimalla 2012a). Diclofenac potassium is a nonsteroidal anti-
inflammatory drug, and has analgesic, antipyretic and anti-inflammatory activity, is poorly 
water-soluble, and served as the model drug. The drug content was 5, 15 and 30 wt% in the 
polymer matrix. Additionally, the versatility of PCL allows it to be blended with many other 
polymers, such as PEG (Grossen et al. 2017), to tune the physical, chemical and mechanical 
properties of devices.  
Polyethylene glycol (PEG), has a high solubility in water. Due to its high hydrophilicity, it 
has been used to improve the hydrophilicity of block copolymers, and enhance water uptake 
and porosity, as well as to modify the degradation properties of copolymers (Stanković et al. 
2013, Stanković et al. 2014). During the melt extrusion process, PEG has been successfully 
utilized as a plasticizer to improve the solubility of a drug in oral administration (Stanković, 
Frijlink, and Hinrichs 2015). Therefore, the combination of PCL with natural and/or synthetic 
polymers may yield different functionalities.  
PCL is also compatible with natural polymers like chitosan and keratin (Tan et al. 2015). 
Chitosan is a polysaccharide found in crab shells and which can be obtained from chitin 




many biomedical purposes due to the relatively cheap price, antimicrobial effects, 
biodegradability and non-toxicity (Tanase and Spiridon 2014). Longer polymers of chitosan 
(with high molecular weight) may be employed as matrix tablet retardants, while shorter 
polymers of chitosan (with low molecular weight) have the ability to improve the water 
solubility of active ingredients in drug release systems (Wolf 2010).  
PCL has also been used to improve the mechanical properties of keratin, and keratin by itself 
is easily degraded and unable to retain structural integrity in aqueous environments alone 
(Edwards et al. 2015). Keratin is the main component of feathers. It contains high quantities 
of cystine and hydroxyl amino acids such as serine (Rouse and Van Dyke 2010). As such, 
keratin offers a wide range of noncovalent and covalent interactions, which makes this natural 
polymer difficult to damage when paired with a polymer (Tanase and Spiridon 2014). 
In light of the literature findings, a ratio of 50:50 by weight of chitosan/keratin (Tran and 
Mututuvari 2015, Vasconcelos and Cavaco-Paulo 2013, Tran, Duri, and Harkins 2013, Sando 
et al. 2010) was selected for this study, as this ratio was seen to be optimal in enhancing the 
properties of the desired suture (Tran and Mututuvari 2015). Furthermore, PCL and PEG 
were added to the blend as well so that the suture has strong basic properties, such as 
increasing solubility of poor water-soluble drug from adding PEG400 (D’souza and Shegokar 
2016), and improving ductility of the sutures due to the addition of PCL (Dash and 
Konkimalla 2012b). Thus, a suture was designed that may have a low enough melting point 
to be produced by melt extrusion method, have low manufacture cost, and have additional 
properties of having a great drug carrying capacity.  
Our hypothesis was that the suture made from PCL/PEG400/chitosan/keratin/ drug not only 
has excellent physicochemical, mechanical and biological properties, but also can exhibit 
controlled drug release.  
2.3 Aims and Objectives 
The overall aim of this study was to develop an absorbable drug-eluting surgical suture using 
a blend of PCL/PEG400/chitosan/keratin and diclofenac potassium (DP) drug. The aim was 
to melt extrude biopolymers and drug DP with the potential for applications in reducing 




The study design includes: 1) fabricating biopolymer sutures via the hot- melt extrusion 
method; 2) characterising the sutures’ physical microarchitecture, chemical makeup, thermal 
and mechanical properties; 3) manufacturing of biopolymer sutures which incorporate the 
drug through the hot- melt extrusion technique; 4) determining drug release profile; and 5) 
investigating the cytotoxicity of the drug-eluting sutures (Figure 7).  
To achieve this aim, the primary objectives were as follows: 
1) Optimize the parameters of hot- melt extrusion techniques for obtaining strong 
and uniform sutures with/without the drug. 
2) Characterise the physical, chemical and mechanical properties and thermal 
properties of the biopolymer sutures that may provide excellent tensile 
strength for surgical applications. 
3) Determine the drug dissolution profiles with drug embedded sutures. 
4) Asses the in vitro biological activity of the drug-eluting sutures. 
 
Figure 7. Summary of The Study Design 
The objectives are from (1) to (5). (1) Fabrication of sutures that contain polymers only. (2) 
Characterisation of melt-extruded sutures with FTIR, TGA. DSC and tensile testing methods. (3) 
Fabrication of sutures that contain both polymers and model drug. (4) Drug dissolution of sutures is 
conducted in PBS solution at pH 7.4. (5) Biocompatibility of sutures contain model drug is 




3 MATERIALS AND METHODS 
3.1 Materials 
The main material of the sutures was the medical-grade polycaprolactone (CAPPA® 6506; 
CAS no: 24980-41-4, Perstorp Holding AB, Sweden). This material is a thermoplastic 
homopolymer with an average molecular weight of 50kDa with a melting point of 58-60° and 
a melt flow index of 11.3-5.2. The second material used was colourless liquid poly(ethylene 
glycol) (Kollisolv® PEG E 400; no.: 25322-68-3, Sigma-Aldrich, USA) with a molecular 
weight of 400 g/mol (PEG400), Tg= -20 °C, Tm= 4 °C. Keratin powder (hydrolysed, code: 
69430-36-0) was supplied by Qingdao Aurora Chemical Co., Ltd., China (Mainland). 
Chitosan (degree of deacetylation, 0.91; Mw=8.9×104 Da) was purchased from Weseta 
international, Shanghai, China. Diclofenac potassium (Voltaren®) was purchased from 
Countdown pharmacy, New Zealand. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; Invitrogen, New Zealand) was used to investigate cytotoxicity of suture 
materials and diclofenac potassium drug. Dulbecco Modified Eagle Medium phenol red 
media (Gibco™, Thermo Fisher Scientific, New Zealand), Dullbecco’s phosphate buffered 
saline (DPBS, Gibco™, New Zealand) and Trypsin-EDTA (Gibco™, Life Technologies 
Corporation, New Zealand) were used for cell media, and cell detachment, respectively, 
during cell culture work. For live/ dead assay, calcein blue AM (CAS no.: 54375-47-2, 
Sigma-Aldrich, USA) and propidium iodide (Cat no.: 421301, BioLegend, USA) were used 
for fluorescence observation.  
3.2 Equipment 
Laboratory designed mini melt-extruder (Billaa-Tex®, TX, USA) was used to prepare sutures 
that were with and without the drug. Differential scanning calorimeter (DSC) Q2000 (TA 
Instruments, MA, USA) and thermogravimetric (TGA) analyser Q50 (TA Instruments, MA, 
USA) were employed to estimate the thermal properties of suture products. Water bath 
(PolyScience, Illinois, USA) was applied to keep the temperature at 37.4 ± 2 °C for the drug 
dissolution test. UV-vis spectrophotometer (Ultrospec 3300 pro, Amersham Bioscience, TX, 




USA) was used to measure the absorbance of cells in 96-well plates. Fourier Transform 
Infrared Spectrometry (FTIR) analysis was used to determine the molecular bonds in the 
selected polymers and carried out using an Alpha II Fourier Transform Infrared Spectrometer 
(Bruker Optik, Germany). The FTIR absorbance spectra were obtained using OPUS software 
(version 5.0, Bruker Optik, Germany). HaCat cells growing in the presence of melt-extruded 
sutures were imaged using an optical Olympus IX71 Inverted Microscope (Olympus 
Corporation, Japan), and the images were analysed using the ImageJ v1.52 software package 
(National Institute of Health, USA). GraphPad Prism 8.3.1 software (USA) was used for 
graphical and statistical analysis of cytotoxicity assays. 
3.3 Suture Preparation for Control Group 
Detailed fabrication procedure is shown as the following steps:  
i. Moisture absorption: before starting the fabrication process, PCL, keratin and 
chitosan were all placed in a desiccator for absorbing moisture of the polymers. 
ii. Five control groups were prepared by pre-weighing 10 g of the mixture of PCL, PEG, 
keratin and chitosan at different ratios (Table 3). Firstly, keratin and chitosan were 
mixed at (50:50) and extracted a certain amount that was required by each formulation. 
Secondly, PCL was added into the keratin-chitosan blend, followed by dripping the 
required amount of PEG into the mixture. Finally, the polymer compound was graded 
thoroughly (Figure 8).  
iii. The five control groups were then prepared by melt extruding in a mixing extruder 
(Figure 9). During the feeding process, the pressure was increased by pushing the 
plug, allowing the material to pass through the feeder and enable the screw that was 
inside the body of the extruder to contact the material fully (Figure 10). Melt blending 
was performed at 60±1, 63±1, 66±1, 69±1, 72±1, 75±1 °C for 5-20 min while the 
roller speed remained unchanged. The extrudates from the die were physically drawn 





Table 3. Control Group (C) (weights/ 10 g in total) 
Control groups, including PCL only; PCL: PEG400 at a ratio of 80:20 wt% PCL: PEG400 
and chitosan-keratin blend mixed together at ratios of 80:19:1, 80:18:2, 80:16:4 wt%. 
C PCL (g) PEG400 (g) Chitosan-Keratin (g) (50:50)  
C1 8 - - 
C2 8 2 - 
C3 8 1.9 0.1 
C4 8 1.8 0.2 
C5 8 1.6 0.4 
 
 
Figure 8. Suture Material Preparation without Drug 
Keratin and chitosan were mixed together with a grinder at a weight ratio of 50:50, followed by 






Figure 9. Mixing Extruder 
A mixing extruder is composed of a feeder, a rotator, a plug and a temperature controller. Motor 
button only can be turned on once the device has reached the operating temperature.  
 
Figure 10. Extruding Process 
During suture fabrication, the plug was placed into the feeder. One hand had to press down the handle 
to increase the surface contact between materials and the screw inside the rotator. The other hand 





3.4 Fourier Transformation-Infrared Spectroscopy 
(FT-IR) 
 
Figure 11. ALPHA FTIR (Bruker) 
In order to confirm the existence of interactions between the API and the carriers, each 
extrudate was pressed into a thin film and calibrated to background spectra. The FTIR spectra 
was obtained by measuring a wavelength ranges from 650 to 4000 cm-1 with a resolution of 
4 cm-1. The final spectrum was the mean of 20 scans. The ATR spectra were converted to 





3.5 Thermal Gravimetric Analysis (TGA) 
 
Figure 12. TGA Q50 
Thermogravimetric analyser (TGA Q50, TA instruments, MA, USA) was utilized to study 
the chemical stability of the carriers and API at elevated temperatures. Samples were heated 
from 20 °C (room temperature) to 800 °C at 10 °C/min and held at an isotherm for 3 min 
(Mohamed et al. 2008). The chambers were flushed with nitrogen at a flow rate of 30 ml/min 





3.6 Differential Scanning Calorimetry Analysis 
(DSC) 
 
Figure 13. DSC Q2000 
DSC can be utilized to study drug-polymer interactions and microparticles as it provides 
information such as melting point, enthalpy of crystallization and glass transition temperature 
(Chen et al. 2016). 
Thermal properties of the extrudates were characterized by using Differential Scanning 
Calorimetry (DSC Q2000, TA instruments, MA, USA). The instrument was calibrated with 
high purity aluminium standards. Samples (5-10 mg) were sealed in aluminium pans with a 
pierced lid. A constant nitrogen flow of 30 ml/min was maintained to provide a constant 
thermal blanket within the DSC cell, thus eliminating thermal gradients and ensuring the 
validity of the applied calibration standard from sample to sample (Palazi et al. 2018, Li, 
Guo, Fan, et al. 2013). Samples were equilibrated for 1 min at 0 °C after which the 
temperature has increased to 200 °C at 10 °C/min, isotherm was maintained for 1 min, and 
the sample was cooled to -70 °C at the same rate, isotherm was maintained for 1 min. The 





3.7 Mechanical Properties 
 
Figure 14. Tensile Analyser 
Before the testing, the diameter of each suture sample was measured three times using a 
digital calliper and a mean diameter was calculated and entered in the Exponent Connect 
Software v7.0 (Stable Micro Systems, UK) for data analysis. The tensile properties of straight 
sutures were investigated with a 50 kg load cell, and at a strain rate of 100 mm/min, using a 
gauge length of 15 mm, at 23 °C. The grips were set to a distance such that the suture material 
was taut, with minimal force (<0.1 N) applied before testing began. For each sample, at least 
five specimens are analysed. If the fibre broke in the clamp, the test was repeated. If the fibre 
slipped out of the clamp during testing, that sample was not included in the calculations of 
mean tensile failure load. If the rupture of sutures happened close to the centre of the active 
length, which indicates that the two points that were griped in the clamp had no effect on the 
results. The average results are reported with their standard deviation (Scaffaro et al. 2013, 





3.8 Suture Preparation for Formulation Group 
Suture preparation for formulation group was conducted using the following steps:  
i. Moisture absorption: Before starting the fabrication process, PCL, keratin and 
chitosan were all placed in a desiccator to absorb the moisture of polymers.  
ii. Nine formulation groups were prepared by pre-weighing 10 g of the mixture of PCL, 
PEG, keratin and chitosan in different ratios shown in Table 4 (Figure 15): Firstly, 3 
groups that contained PCL/PEG400/chitosan-keratin, PCL/PEG400/chitosan, and 
PCL/PEG400/keratin were prepared (Figure 16). For group 1, keratin and chitosan 
(50:50) were blended together by a certain amount that was required for each 
formulation. PCL (as white powder) was added into the keratin-chitosan blend, 
followed by dripping a certain amount of liquid polymer PEG into the mixture and 
then grinding the polymer compound thoroughly. The preparation of group 2 and 
group 3 followed similar instructions. Secondly, the drug tablets were manually 
ground into fine powder in a grinder. To achieve 5, 15 and 30 wt% of drug content, 
the ratio of polymer blend and drug were set as 95:5, 85:15, and 70:30 wt%. Briefly, 
a certain amount of polymer compound (1.9 g, 1.7 g or 1.4 g) was extracted, mixing 
with the required amount of drug powder (0.1 g, 0.3 g or 0.6 g), resulted in a total 
amount of 2 g (Table 4). Finally, the mixture was grounded thoroughly and fed into 
the extruder. 
iii. The nine formulation groups were then prepared by melt mixing in a mixing extruder 
(Figure 9). During the feeding process, the material mixture was pushed by the plug 
to increase pressure, which allowed materials to pass through the feeder and enabled 
the screw to fully contact the materials. Melt blending was performed at 63±1°C for 
5-20 min with no change in roller speed. The extrudates from the die were physically 
drawn into fine fibres. The extruding order was group 2, F4, F5, F6, group 1, F1, F2, 
F3, group 3, F7, F8, F9. The reason that extruding groups 1, 2, 3 were placed between 
different polymer groups was to eliminate the possibility of introducing unwanted 
material into the desired polymer group. All samples after preparation were placed at 





Table 4. Formulation Group (F) (weights/ 10 g in total) 
According to the characterisation study of the control group sutures, PCL: PEG400: 
chitosan/keratin= 8:1.9:0.1 (Group 1) was confirmed to be the ideal weight ratio group. 
PCL/PEG/chitosan (Group 2) and PCL/PEG/keratin (Group 3) were designed to compare 
with Group 1. 







Keratin (g) Diclofenac 
(g) 
F1 8 1.9 0.1 - - 0.1 
F2 8 1.9 0.1 - - 0.3 
F3 8 1.9 0.1 - - 0.6 
F4 8 1.9 - 0.1 - 0.1 
F5 8 1.9 - 0.1 - 0.3 
F6 8 1.9 - 0.1 - 0.6 
F7 8 1.9 - - 0.1 0.1 
F8 8 1.9 - - 0.1 0.3 







Figure 15. Suture Material Preparation with Drug 
Keratin and chitosan were mixed together at a weight ratio of 50:50, followed by blending with PCL and 
PEG. Finally, certain amount of drug was added into mixture and blended thoroughly. 
 
Figure 16. Groups 1, 2, 3 Mixtures 
The mixtures were in white powder forms. All the mixtures tended to form lumps, due to the presence 




3.9 Drug Release Studies 
3.9.1 Standard Preparation 
To begin the experiment, phosphate-buffered saline (PBS) solution was prepared by pouring 
1 packet of dry powder of phosphate-buffered saline into 1000 ml of distilled water. After 
stirring with a magnetic stirrer, the PBS was completely dissolved in the water with pH of 
7.4 ± 0.2. For calibration purposes, 100 mg drug was dissolved in 100 ml PBS solution with 
pH 7.4 and this served as the stock solution. From this stock solution, 5 ml was pipetted into 
a 10 ml volumetric flask and diluted up to 10 ml with PBS. Followed by taking 5 ml solution 
out of the 10 ml volumetric flask and diluted to another 10 ml volumetric flask. The 
aforementioned process was repeated for 3 more times to obtain a sequential dilution with 
concentrations of 0.0312, 0.0625, 0.125, 0.25, 0.5 mg/ml respectively. The dilutions were 
analysed for absorbance at 276 nm using the UV-Visible spectrometer. The curve generated 
by concentrations and wavelengths exhibited behaviour over the full range of concentrations.  
3.9.2 In vitro Drug Release Study 
For the drug release study, nine different types of sutures were immersed in nine 50 ml falcon 
tubes which contained 30 mL 0.01 M of PBS buffer. Each tube contained sutures of 2 g based 
on Table 4. The reference tube contained sutures extruded from all the polymers (i.e. PCL, 
PEG400, keratin and chitosan). Tubes were immersed in a water bath (Daihan Scientific 
WCB-11) (Figure 17) for various periods of time under gentle stirring. The temperature of 
the solution was maintained at 37.4 ± 2 °C at all times.  
The released media (5 mL) was extracted and replaced with the same volume of fresh PBS 
at time intervals of every 0.25, 0.5, 1, 2, 3 hr (i.e. 15mins, 45mins, 1h 45mins, 3h 45mins, 6h 
45mins). The samples were analysed via measuring the absorbance at 276 nm wavelength 
with a UV-vis spectrophotometer (Ultrospec 3300 pro, Amersham Bioscience) (Figure 18) 
and then compared to the predetermined calibration curve to obtain concentrations. The 






Figure 17. Suture Immersion  
Nine 50 mL centrifuge tubes were placed in a water bath. Each tube contained 2 g of sutures 
 





3.10 Biocompatibility Tests 
3.10.1 Cell Lines and Maintenance 
Human keratinocytes cell line (HaCat ATCC® CRL-2404) are the one of the most abundant 
cells in adult human skin, widely used in scientific research. HaCat was used as a model cell 
line to evaluate the cytotoxicity of the drug-embedded polymer sutures. Frozen stocks of 
HaCats were extracted from liquid nitrogen tank and then quickly warmed up in a water bath 
under temperature of 37°C (Figure 19). Cell proliferation procedure was conducted in a 
Herasafe 2030i biological safety cabinet (Thermo Fisher Scientific, USA) (Figure 20), which 
was disinfected with UV light and 70% ethanol. 
Complete DMEM (cDMEM) was prepared with DMEM red media (pH:7.4) enriched with 
10% foetal calf serum (FCS, Gibco™, Thermo Fisher Scientific, Waltham, MA, USA) and 
1% penicillin and streptomycin (PenStrep, Sigma-Aldrich). Thawed HaCat cell line was then 
transferred to a 75 cm2 flask containing cDMEM. The flask was kept inside a CO2 incubator 
(Heraeus® Heracell®) (Figure 21), set at 37 °C with a 5% CO2 (95% air) atmosphere for a 
week, the media was changed once every three days. Once cells were passaged at 80% 
confluency, the media was removed and cells were washed with Dullbecco’s phosphate 
buffered saline (DPBS, Gibco™), and adding 3 mL Trypsin-EDTA (Gibco™, Life 
Technologies Corporation) to detach cells. Please note that the Trypsin-EDTA requires to be 
warmed in a water bath (Figure 19) at 37°C before using to prevent shocking cells. The flask 
was then incubated for 6 mins to allow for the trypsinization of the cells. Followed by 
inactivating trypsin with 6mL cDMEM. The solution was then removed to 15 mL tubes and 
the cell number was counted using a handheld automated cell counter (Scepter™) (Figure 22). 
Solution (1 mL) from the flask was re-subcultured in each new flask containing 25mL 
cDMEM. According to the cell number requirement for MTT, live/dead, scratch assays, the 






Figure 19. Thermo Scientific Liquid Nitrogen Tank & Water Bath 
Frozen stocks of HaCat cells were stored inside the nitrogen tank. To defrost the cell line, tubes 
needed to be immersed in the water bath at 37 °C. 
 
Figure 20 Herasafe KS Class П Biosafety Cabinet 






Figure 21 CO2 Incubator & Flasks of Complete DMEM 
After completing cDMEM preparation, all the flasks were stored inside the CO2 Incubator. 
 
Figure 22. Handled Automated Cell Counter 






3.10.2 Cell Viability in Response to Suture Materials 
Estimation of suture cytotoxicity was performed by direct contact of HaCat with polymer-
drug suture materials. To prepare the samples, the fabricated polymer suture and polymer-
drug suture were cut into 1 cm length (Obermeier et al. 2015, Umair et al. 2015). Washed 
with distilled water and sprayed with 70% ethanol. All these samples were exposed to 
ultraviolet light for 1 h before the addition of the cells to minimize contamination 
(Adomaviciute et al. 2018). 
Cell viability of HaCat in response to sutures was determined using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay. This 
colorimetric assay determines the cell number by measuring the amount of purple formazan 
crystals formed when mitochondrial reductases (present in viable cells) reduce the yellow 
dye, MTT. This study was conducted in a 96-well plate. For formulation group and control 
group, 5 x 103 cells/ml were seeded into each well. Standard curve was ranged from 2.5 to 
80 x 103 cells/ml cells (Figure 23). All the cells were left in the plates for 24 hours, attaching 
to the bottom of the each well. Cells were then treated for 24, 48 and 72 hours in the presence 
of sutures that are shown in Table 5 and Table 6. Each cultivation was performed in triplicate. 
Stock MTT was prepared at 5 mg/ml in PBS, 600 µL MTT stock was then extracted and 
diluted with 3 mL cDMEM colour free to achieve a final concentration of 0.4 mg/mL. After 
this, media was removed and 300 µL MTT solution was added into each well. Followed by 
incubating plates for 4 hours. After that, the MTT solution was extracted and the formazan 
crystals were left in plates. To dissolve the crystals, 100 μL of 10% SDS/1M HCL (100:1) 
were added to each well. After that, the plates were incubated at 37 °C overnight in the CO2 
incubator. Absorbance results were obtained at a wavelength of 620 nm with Gen5 software 





Table 5. Control Group 
To investigate the effect of polymers on the cell proliferation, pure PCL, PCL/PEG and 
PCL/PEG/chitosan/keratin extrudates were designed as control group. 







Keratin (g) Diclofenac 
(g) 
C1 8 - - - - - 
C2 8 1.9 - - - - 
C3 8 1.9 0.1 - - - 
Table 6. Experimental Group 
Group 1, 2, 3 with various drug content were designed as experimental group. 







Keratin (g) Diclofenac 
(g) 
F1 8 1.9 0.1 - - 0.1 
F2 8 1.9 0.1 - - 0.3 
F3 8 1.9 0.1 - - 0.6 
F4 8 1.9 - 0.1 - 0.1 
F5 8 1.9 - 0.1 - 0.3 
F6 8 1.9 - 0.1 - 0.6 
F7 8 1.9 - - 0.1 0.1 
F8 8 1.9 - - 0.1 0.3 







Figure 23. Plate Design for MTT Assay 
Experimental group, control group, and standard curves were assembled in two 96-well plates. 
Adding suture only group was to confirm whether the MTT solution would make colour change of 
sutures. 
 





3.10.3 Fluorescence Microscopy 
Biocompatibility of the sutures was analysed in triplicate using the live/dead assay. 
Fluorescence staining was applied to observe the cells that were under direct contact with 
melt-extruded sutures. In order to investigate the number of dead cells and live cells at time 
intervals of 24, 48 and 72 h. Coverslips were immersed in 70% ethanol before placing into 
24-well plates. Sutures were cut into 1 cm length for each well. Each well contained 500 µL 
DMEM media and 5 x 103 cells/ml cells (Figure 25). HaCat cells were treated for 24, 48, 72h 
through direct contact tests. After the treatment, a solution containing 4.5 µL calcein-AM 
(acetomethoxy derivate of calcein) and 18 µL ethidium homodimer-1 in 3 mL PBS was made. 
For some samples, 30 µL of the solution was pipetted onto a glass slide and covered with a 
coverslip, the side that contained cells faced the slide. For the rest of samples, the 30µL of 
the solution was pipetted onto each coverslip in the 24-well plates. Afterwards, images were 
taken using an IX71 inverted fluorescent microscope (Olympus) using a 10x objective 
(Figure 26). The analysis was done by using ImageJ software. The number of live or dead 
cells were quantified according to the following Eq. (1): 






Figure 25. Plate Design for Live/Dead Assay 
Formulation group, control group and cell only were seeded in 24-well plates.  
 





3.10.4 Wound Healing in Response to Suture Materials 
The scratch assay (injury to the cell monolayer) was performed in triplicate, to quantify the 
spreading and migration capabilities of cells exposed to the samples. HaCat cells were seeded 
in a 48-well plate at 40 x 103 cells/ml per well (Figure 27) and incubated in 5% CO2 at 37 °C 
for 24 h. After the cells grew to over 90% confluence, a straight scratch was created with a 
sterile 100 µl pipette tip. Afterwards, group 1 sutures were cut into 1cm length and placed 
into wells. Only group 1 with the formulation of PCL/PEG400/chitosan/keratin was chosen 
to be the formulation group due to its better performance in MTT and live/dead assays. 
Control group contained 3 suture groups: PCL only, PCL/PEG400 and 
PCL/PEG400/chitosan/keratin. Cells cultured with DMEM alone served as a control. Images 
of the closure scratch were captured at 0, 6 and 24 h using a Ceti Magnum Trinocular 
compound microscope (Figure 28). Before capturing the images, a dot was drawn on the 
bottom of each well to make the scratch area easy to find. The residual gap between the 
migrating cells was measured and expressed as percentage migration rate using the following 
Eq. (2): 







Figure 27. Plate Design for Scratch Assay 
Experimental group and control group are assembled in a 48-well plate. 
 





Before mixing the drug with the biopolymer materials to study the drug release profile, it was 
important to estimate the biopolymer sutures at the molecular level, and to investigate their 
thermal properties and mechanical properties. The overall aims were, 1) To optimise polymer 
formulations with hot- melt extrusion technique to provide a robust polymer matrix in which 
to embed drug particles. 2) To achieve solid dispersion of the polymer-carriers and drug with 
the hot- melt extrusion technique. 3) Optimise drug/polymer formulations using drug 
dissolution and biocompatibility assays. For these reasons, a wide range of polymer and drug 
ratios were investigated. The specific objectives were:  
1. Polymer suture fabrication. 
2. To investigate the characterisation of the biopolymer materials, using FTIR, 
DSC, TGA and tensile analyser.  
3. To optimise the drug/polymer suture fabrication processes. 
4. To investigate the drug release profile using a drug dissolution test. 
5. To investigate the drug/polymer in vitro cytotoxicity, by using the MTT, 
live/dead and scratch assays.  
4.1 Suture Preparation for the Control Groups 
4.1.1. Melt Extruder 
It is important to note that the only method to clean the melt extruder is to extrude the acquired 
material until the machine only contains the material that is wanted. For the machine cleaning 
purpose, PCL was used to purge the machine. At first, since the remaining material inside the 
device was unknown, the purging temperature was set higher than the melting point of PCL 
(80 °C), but nothing came out of the nozzle. The temperature was then gradually increased 
to 96 °C, 117°C and 150 °C. In the temperature increasing process, blackish material came 




extrudate was entirely dark in colour. Once the machine was cool, the material would fix the 
screw and the machine could not rotate. Therefore, it required frequent cleaning during the 
purging process. 
4.1.2 Melt Extrusion at 63±1 °C 
To remove the residual material from previous the usage, the extruder was purged with pure 
PCL for 10 minutes, and the extrudates began to appear transparent and colourless. When the 
extruder contained only the required polymer, PCL, the temperature was adjusted the  to reach 
60±1°C followed by gradually increasing temperature to 63±1 °C, 66±1 °C, 69±1 °C, 72±1 
°C, 75±1 °C. When the temperature reached 63±1 °C, the polymer powder was melted at the 
expected rate, which allowed the collection of fibres with an even surface. However, when 
materials were heated at 75±1°C, they became too liquid to collect into the fibre form. 
The components of each control group are shown in Table 7. Extrudates were all obtained as 
fishing line-like fibres. The extrudates of pure PCL were soft, clear and transparent when 
coming out of the nozzle, turning to white solid fibres after being exposed to air for half a 
minute. The extrudates of C3 (0.6 mm), C4 (0.6 mm) and C5 (0.9 mm) were thicker than 
Control groups C1 (0.5 mm) and C2 (0.4 mm). The three groups (C3, C4, C5) were also not 
homogeneous, and had lumps on the fibre surfaces which were hard to notice without 
touching. It was difficult to obtain long fibres, the filament of C3 would break when the length 
reached about 38 cm (Figure 29). Both C4 and C5 extruded relatively long fibres (Figure 30), 
especially C5, which contained higher amounts of chitosan/keratin, extruded with fibre length 





Table 7. The Physical Observations of Extruded Polymer Fibres 












C1 8 - - 0.5 
Homogeneous with high ductility; 
white 
C2 8 2 - 0.4 Homogenous; grey 
C3 8 1.9 0.1 0.6 Inhomogeneous; grey 
C4 8 1.8 0.2 0.6 Inhomogeneous; grey 
C5 8 1.6 0.4 0.9 
More stable extruding rate than C3 
or C4; inhomogeneous; white 
 
 






Figure 30. Extrudates of Sample C4 & C5 at 63±1 °C  
Extrudate C5 demonstrated a more brittle physical property than extrudate C4, attributed to the 
higher content of chitosan/keratin.  
 






Figure 32. Extrudates of C5 at Variable Temperatures 
When T= 63±1 °C, the extrudates were fine and extruded with stable extruding rate. When T= 66±1 
°C, the extruding rate of extrudates became unstable. When T= 69±1, 72±1, 75±1 °C, extrudates were 
impossible to be collected in a fine filament form.  
 





4.1.3 Melt Extrusion at Various Temperatures 
Even a slight temperature change may largely affect the extrusion rate and extrudate 
properties. This was demonstrated by the control groups that contain PCL, PEG400 and 
chitosan/keratin. The resulting change in properties are shown in Table 8. When the 
temperature was set at 60±1 °C, the powder blend could not melt inside the extruder and no 
extrudate came out of the nozzle. Figure 32 shows extrudates of control group 5 at different 
temperatures. When the temperature was set at 63±1 °C, it was able to obtain fine fibres with 
a stable extruding rate. Raising the temperature to 66±1 °C, the extrudates were still relatively 
fine but under an unstable extruding rate, this caused difficulty in fibre collection. With the 
increase in temperature, extrudates were gradually liquefying and air pocket formation was 
observed followed by hearing a “bubble breaking sound”, which resulted in the impossibility 
of collecting products in filament form (temperature at 69±1,72±1 and 75±1 °C). Please note 
that the temperature fluctuation of 1 degree Celsius reflects the temperature controller 
readings, which fluctuated ±1 degree. The only way to adjust the temperature was to slightly 
turn the indicator and carefully observe the temperature change (Figure 33). 
Table 8 Control Group (contains PCL+PEG400+Chitosan/keratin) at Various 
Temperatures 
Control group C3, C4 and C5 demonstrated similar physical properties at temperatures of 
60±1 °C, 63±1 °C, 66±1 °C, 69±1 °C, 72±1 °C, 75±1 °C. 
Temperature °C Physical properties 
60±1 Powder could not melt 
63±1 Fine and long fibres 
66±1 Relatively fine fibres but not under stable extruding rates 
69±1 Liquid extrudates 
72±1 Very liquid extrudates 





4.2 Summary of Biomaterial Production and Suture 
Generation 
The optimization results showed that: 
⚫ It was important to purge melt extruder with a temperate higher than the melting 
point of PCL. The certain purge temperature depended on the previous materials 
used in the machine.  
⚫ 63±1 °C is the optimum heating temperature for biomaterials to be melted effectively 
for extrusion. 
⚫ Sutures that contain chitosan/keratin tend to be slightly thicker than sutures made 
with PCL only or PCL/PEG blend.  





4.3 Fourier-Transform Infrared Spectroscopy 
FTIR spectra of different material sutures are shown in Figure 34. PCL (C1) showed peaks 
around 2943 cm-1, 2866 cm-1, 1721 cm-1, 1293 cm-1, 1238 cm-1, 1163 cm-1, and 1106 cm-1 
(Table 9). There was a significant difference in the spectra of PCL and the PCL/PEG blend 
(C2) demonstrated by a sharp peak at 3441 cm-1, indicating the presence of hydroxyl groups 
(OH). These spectral characteristics did not change with the addition of chitosan/keratin 
blend (C3, C4, C5). 
Table 9. Functional Groups of PCL 
Position (cm-1) Vibrator Abbreviation 
2943 –C–H asymmetric stretching νas(CH2) 
2866 –C–H symmetric stretching νs(CH2) 
1721 –C=O stretching ν(C=O) 
1293 C–O and C–C stretching in the crystalline phase νcr 
1238 Asymmetric COC stretching νas(COC) 
1163 C–O and C–C stretching in the amorphous phase νam 








































































Figure 34. FTIR Spectra of Individual Samples and Overlay Graph 
Individual Spectra of pure PCL, PCL/PEG and individual spectra from different formulation of 
PCL/PEG/Chitosan/Keratin are shown, the spectra of the overlay of all the ingredients and samples 
are shown. a) PCL, b) PCL+PEG400, c) PCL+PEG400+chitosan-keratin=80:19:1 w/w, d) 
PCL+PEG400+chitosan-keratin=80:18:2 w/w, e) PCL+PEG400+chitosan-keratin=80:16:4 w/w, f) 
spectra of all the ingredients and samples. Data were acquired and graphed using OPUS software 
and shown in transmittance. Individual spectral images were used for peak analysis. Arrows indicate 
the peaks of interest.  
–C=O C–O 
COC C–O/C–C 





4.4 Thermal Testing 
4.4.1 TGA 
TGA graphs of all the extruded samples are shown in Figure 35. Sutures were heated from 
20 °C (room temperature) to 800 °C at 10°C/min and held at an isotherm for 3 min (Mohamed 
et al. 2008). All the samples showed a simple one-step decomposition profile with a single 
transition temperature, as demonstrated by TGA. The sample degradation profile which 
contains PCL: PEG: chitosan/keratin=80:16:4 (w/w) (C5) showed a higher thermal stability 
than the rest of samples, it started degrading at 377 °C and completely decomposed (0% w/w) 
at 778 °C, whereas pure PCL (C1) started degrading at 374 °C and degraded completely at 
559 °C. With PCL: PEG4: chitosan/keratin= 8:18:2 (w/w) (C4), the sample was not fully 
degraded until after 800 °C. PCL and PEG blend (C2) showed the lowest thermal stability, it 
started to degrade at 325 °C, when the temperature reached 340 °C, half the sample degraded 
and fully decomposed at 477 °C. Overall, C3 exhibited a relatively slow and steady 










































Figure 35. TGA Curves of Individual Samples and Overlay Graph 
a) PCL, b) PCL+PEG400, c) PCL+PEG400+chitosan-keratin=80:19:1 w/w, d) 
PCL+PEG400+chitosan-keratin=80:18:2 w/w, e) PCL+PEG400+chitosan-keratin=80:16:4 w/w, f) 
overlay graph of all the samples. Data were acquired and graphed using the TA Instruments Software 
Universal Analysis (TA Instruments, MA, USA). Individual graphs of pure PCL, PCL/PEG and 






The DSC profiles of the pure PCL and PCL-based composites are shown in Figure 36. All 
the samples were reheated to eliminate thermal history. Each sample included a glass 
transition (Tg), endothermic during heating (melting), and exothermic during cooling 
(crystallization). The corresponding heat capacity (ΔCp) and Tg temperatures obtained from 
the DSC data of the pure PCL and its composites are shown in Table 10, 11, 12. Pure PCL 
(C1) showed the highest Tg temperature at -68.91 °C, whereas the polymer composite of PCL: 
PEG: chitosan/ keratin=80:18:2 (w/w) (C4) demonstrated the highest heat capacity of 3.48 
J/(g°C). When the ratio of PEG: chitosan/ keratin was 19:1 (w/w) (C3), crystallization point 
was the lowest compared to the other two ratios, which indicated that C3 has lower 
crystallinity. 
Table 10. Summary of Differential Scanning Calorimetry Analysis of Samples 
The glass transition temperatures and heat capacities of sample C1, C2, C3, C4 and C5 are 
shown below: 
Thermal property Sample Temperature (°C) Heat capacity 
(J/(g°C) 
Glass transition 
C1 -68.91 0.77 
C2 -69.01 2.32 
C3 -69.31 3.14 
C4 -69.41 3.48 






Table 11. Endothermic Transition for Each Thermal Property  
Thermal property Sample Temperature (°C) 
Melting onset  C1 50.53 
 C2 51.31 
 C3 50.71 
 C4 50.22 
 C5 50.08 
Melting peak  C1 56.68 
 C2 55.96 
 C3 55.31 
 C4 54.57 
 C5 54.61 
Table 12 Exothermic Transition for Each Thermal Property 
Thermal property Sample Temperature 1 (°C) Temperature 2 
(°C) 
Cooling onset C1 31.64 - 
 C2 32.08 -30.79 
 C3 31.75 -32.38 
 C4 32.35 -32.52 
 C5 32.17 -31.6 
Cooling peak C1 28.04 - 
 C2 30.04 -34 
 C3 29.15 -36.08 
 C4 30.79 -35.39 





































Figure 36. DSC Curves of Individual Samples and Overlay Graph 
a) PCL, b) PCL+PEG400, c) PCL+PEG400+chitosan-keratin=80:19:1 w/w, d) 
PCL+PEG400+chitosan-keratin=80:18:2 w/w, e) PCL+PEG400+chitosan-keratin=80:16:4 w/w, f) 
overlay graph of all the samples. Data were acquired and graphed using the TA Instruments Software 
Universal Analysis (TA Instruments, MA, USA). Individual graphs of pure PCL, PCL/PEG and 




4.5 Tensile Testing 
Tensile testing results were obtained by using the tensile analyser (Figure 14). The results of 
tensile testing were demonstrated with all major data sets (failure load, elongation at break, 
tensile strength, and Young’s modulus). Mean and standard deviation values of diameter 
(mm), failure load (N), elongation at break (%), tensile strength (MPa) and young’s modulus 
(MPa) are presented for all samples in Table 13.  
Curves for all samples comparing stress to strain are shown in Figure 37 (a) and the values 
of tensile strength are shown in Figure 37 (b). The failure load and elongation of all samples 
are shown in Figure 38 (a, b). Young’s modulus results are displayed in Figure 39.  
C5 has the highest failure load, which would make a good choice for high tension areas, such 
as scalp wound closures. C1 allowed for the most elongation before breaking, corresponding 
to its high ductility. Increased elongation would be advantageous in situations where a great 
deal of oedema is expected postoperatively. The values of the tensile strength of samples can 
determine the highest strength material independent of diameter. The stress-strain curves and 
tensile strength as shown in Figure 37 (a, b) exhibited that C1 and C3 have the highest tensile 
strength, which means C1, C3 have stronger mechanical properties than the rest of the 
samples. The higher Young’s modulus value of C3 demonstrated the higher stiffness of the 
sample (Figure 39).  
Overall, C3 is a relatively strong and stiff material with proper elongation, which requires 






Table 13. Summary of Mechanical Testing Analysis of Suture Samples 
Sample results of diameter, failure load, elongation at break, tensile strength and young’s 


























































Figure 37. Tensile Properties of Suture Samples 
Samples of pure PCL, PCL/PEG, and different formulations of PCL/PEG/chitosan/keratin were 
measured (a) stress versus strain before deformation; (b) the values of tensile strength. Each bar was 





Figure 38. Ductile Failure of Suture Samples 
Samples of pure PCL, PCL/PEG, and different formulations of PCL/PEG/chitosan/keratin were 
measured for (a) failure load;(b) elongation at break. Each bar was presented with mean value and 
standard deviation.  
 
 
Figure 39. Young’s Modulus of Suture Samples 
Samples of pure PCL, PCL/PEG, and different formulations of PCL/PEG/chitosan/keratin were 




4.6 Summary of Suture Characteristics  


















C1 PCL 0.5 56.68 -68.91 374.62 20.7 












0.9 54.61 -69.20 377.69 16.4 
The comparison of characterisation of different suture formulations are listed in table 14. The 
studies concluded: 
⚫ FTIR analysis showed that, except for the presence of hydroxyl groups (OH) in the 
spectrum of C2 (PCL/PEG400 blend) compared to C1 (PCL only), the addition of 
chitosan/keratin did not generate new molecular bonds (C3, C4, C5).  
⚫ Sutures that contained PCL/PEG400/chitosan/keratin exhibited a relatively slow and 
steady decomposition rate in comparison to the PCL alone and PCL/PEG400 blend 
sutures. 
⚫ All the samples presented a single Tg, which indicates the miscibility or interaction 
of molecules. And the addition of the PEG400/chitosan/keratin in the PCL reduced 
the melting point and glass transition temperatures.  
⚫ Amongst all five samples, C3 (PCL/PEG400/chitosan/keratin blend) is the most 
ideal candidate for surgical suture application, due to its relatively strong and stiff 





4.7 Suture Preparation for the Formulation Groups 
Polymers were split into three groups: group 1 contained PCL, PEG400, chitosan/keratin 
(Table 15); group 2 consisted of PCL, PEG400, chitosan (Table 16); group 3 was composed 
of PCL, PEG400, keratin (Table 17). Three polymer groups were extruded with drug DP 
respectively. The drug percentage in the compound was 5, 15, 30 wt%.  
F1, F4 and F7 had the lowest drug content, the extruding process was consistent, thus, a 
uniform thickness was easy to achieve. Additionally, the extrudates were relatively white 
with a smooth surface. F2, F5 and F8 were extruded with a higher drug percentage. Products 
maintained uniform thickness but the colour turned yellowish. F3, F6 and F9 consisted of the 
highest drug content of 30%. Due to the drug additives, those with a lower melting 
temperature such as glucose and starch, and those with a higher melting temperature such as 
diclofenac potassium, extrudates were greyish with many visible white lumps on the surface, 
which caused the brittleness of the fibres (Figure 40). Interestingly, under the same drug load, 
fibres contained PCL/PEG400/chitosan were slightly thinner (0.8 mm) than fibres that 





Table 15. Summary of Suture Preparation for Group 1 
Group 1 contained PCL, PEG400, chitosan/keratin and drug, melt-extruded at 63±1 °C 








F1 8 1.9 0.1 0.1 White, 
smooth 
F2 8 1.9 0.1 0.3 Yellow, 
smooth 
F3 8 1.9 0.1 0.6 Grey, rough 
Table 16. Summary of Suture Preparation for Group 2 
Group 2 contained PCL, PEG400, chitosan and drug, melt-extruded at 63±1 °C 





F4 8 1.9 0.1 0.1 White, 
smooth 
F5 8 1.9 0.1 0.3 Grey, smooth 
F6 8 1.9 0.1 0.6 Grey, rough 
Table 17. Summary of Suture Preparation for Group 3 
Group 3 contained PCL, PEG400, keratin and drug, melt-extruded at 63±1 °C 





F7 8 1.9 0.1 0.1 White, smooth 
F8 8 1.9 0.1 0.3 Dark grey, 
smooth 








Figure 40. Extrudates of Suture Samples Contained Drug 
Group 1 (F1, F2, F3) contained PCL, PEG, chitosan, keratin and drug; group 2 (F4, F5, F6) 
contained PCL, PEG, chitosan and drug; group 3 (F7, F8, F9) contained PCL, PEG, keratin and 
drug, were melt-extruded at 63±1 °C. F1, F4, F7 contained 5% of drug; F2, F5, F8 contained 15% 





4.8 Drug Dissolution Testing 
4.8.1 Calibration Curve 
A calibration curve was generated by measuring absorbances at 276 nm, based on known 
drug concentrations of 0.0312, 0.0625, 0.125, 0.25, 0.5 mg/mL (Table 18). The profile is 
shown at Figure 41. 
Table 18. Absorbances of Known Concentrations of Drug in Phosphate Buffer at pH 
7.4 
Five concentrations of drug were measured at absorbance of 276 nm using the UV-Visible 
spectrometer. It can be seen that absorbance is increasing with higher concentration of drug. 
Serial number Concentration (mg/mL) Absorbance at 276 nm 
1 0.0312 0.013 
2 0.0625 0.025 
3 0.125 0.053 
4 0.25 0.098 







Figure 41. Standard Curve of Drug in Phosphate Buffer at pH 7.4. 
The calibration curve was used for calculating the unknown concentrations with known 




































4.8.2 Drug Release Profiles 
Nine formulations were divided into three groups which contained different polymer blends, 
as shown in table 19. Group 1= PCL/PEG400/chitosan/keratin/drug; Group 2= 
PCL/PEG400/chitosan/drug; Group 3= PCL/PEG400/keratin/drug. Each group comprised an 
embedded drug amount of 5, 15 and 30%. All sutures were placed into tubes that contained 
phosphate buffer at pH 7.4 and immersed into a water bath. 
F1, F2 and F3 are composed of PCL, PEG, chitosan/keratin blend and drug. The drug content 
of F1, F2 and F3 was 5, 15, 30% respectively. Before 1.75 h, the drug dissolved slowly from 
the polymer matrices of F1, F2 and F3. After the point of 1.75 h, the drug release rate slightly 
increased until 6.75 h. Three formulations demonstrated similar drug release patterns, which 
indicated that the drug content had little impact on the polymer matrices (Figure 42).  
F4, F5 and F6 consist of PCL, PEG, chitosan and drug. The drug content of F4, F5 and F6 
was 5, 15, 30% respectively. F5 and F6 demonstrated similar drug release patterns, drug 
dissolution rate slightly improved between a time interval of 1.75 and 3.75h. On the other 
hand, F4 exhibited a sustained release at all times. Between 1.75 h and 3.75h, the drug 
concentration increased by 70% in F4 and F6. After 3.75h, the release rate slowed down, but 
was still quicker than the initial release rate. Surprisingly, F5 had a lower concentration than 
F4 the entire experimental time. However, at 3.75 h, the concentration gap between F4 and 
F5 narrowed dramatically, and so it can be predicted that a cross point will be seen after 
several hours (Figure 43), due to the relatively fast degrading material PEG400, since its 
degradation could last up to 3 days (Browning et al. 2014). 
F7, F8 and F9 are composed of PCL, PEG, keratin and drug. The drug content of F7, F8 and 
F9 was 5, 15, 30% respectively. This group contained polymer blend of PCL, PEG400 and 
keratin. All the formulations exhibited a rapid drug release profile for the first 1.75 h, and the 
plateau state achieved at 3.75 h. These polymer groups generated a rapid drug release profile 
(Figure 44).  
F3, F6 and F9 contained the highest amount of drug diclofenac (0.6 g) in their groups. 
Comparing these three formulations, F9 demonstrated the fastest drug release profile. The 
polymer matrices that contained PCL, PEG400, chitosan (F6) and PCL, PEG400, chitosan-




stable controlled release rate than F6, which is an ideal candidate for controlling diclofenac 
release inside the human body (Figure 45). 
Table 19. Concentrations of Dissolution Media at Different Time Intervals. 
Group 1 (F1, F2, F3) consisted of PCL, PEG, chitosan, keratin and drug; group 2 (F4, F5, 
F6) contained PCL, PEG, chitosan and drug; group 3 (F7, F8, F9) was composed of PCL, 
PEG, keratin and drug. F1, F4, F7 contained 5% drug; F2, F5, F8 contained 15% drug; F3, 
F6, F9 contained 30% drug. Dissolution media were extracted at time intervals of 15 minutes, 
30 minutes, 1 hours, 2 hours and 3 hours.  
 
0.25 0.75 1.75 3.75 6.75 
F1 0.013 0.034 0.072 0.242 0.398 
F2 0.187 0.218 0.327 0.559 0.739 
F3 0.379 0.456 0.565 0.840 1.109 
F4 0.294 0.395 0.492 0.709 0.874 
F5 0.111 0.175 0.236 0.575 0.767 
F6 0.327 0.477 0.565 0.977 1.200 
F7 0.089 0.199 0.318 0.520 0.535 
F8 0.099 0.242 0.428 0.620 0.688 










Figure 42. Dissolution of Group 1 (F1, F2, F3) in Phosphate Buffer at pH 7.4  
Group 1 (F1, F2, F3) contained PCL, PEG, chitosan, keratin and drug. The drug content of F1, F2 
and F3 were 5%, 15% and 30%, respectively.  
 
 
Figure 43. Dissolution of Group 2 (F4, F5, F6) in Phosphate Buffer at pH 7.4 
Group 2 (F4, F5, F6) contained PCL, PEG, chitosan and drug. The drug content of F4, F5 and F6 





Figure 44. Dissolution of Group 3 (F7, F8, F9) in Phosphate Buffer at pH 7.4 
Group 3 (F7, F8, F9) contained PCL, PEG, keratin and drug. The drug content of F7, F8 and F9 
were 5%, 15% and 30%, respectively. 
  
Figure 45. Comparison of F3, F6 and F9 in Phosphate Buffer at pH 7.4 
Group 4 (F3, F6, F9) contained 30% of drug. The formulations of F3, F6 and F9 were 





4.9 Summary of Drug-Eluting Suture Fabrication 
and Drug Dissolution 
The suture generation and drug dissolution profiles indicated that: 
⚫ Sutures that contained lower drug amounts demonstrated relatively white 
fibres with a smooth surface. Whereas, sutures with higher drug amount 
showed greyish colour with visible white lumps on the surfaces. Moreover, 
extrudates contained PCL/PEG400/chitosan were slightly less thick (0.8 mm) 
than fibres that contained PCL/PEG400/keratin (0.9 mm) and 
PCL/PEG400/chitosan/keratin (0.9 mm) 
⚫ Group 3 (PCL/PEG/keratin/drug) demonstrated a rapid release profile. 
Whereas, Group 1 (PCL/PEG/chitosan/keratin/drug) and Group 2 
(PCL/PEG/chitosan/drug) generated a controlled drug release profile. The 
release rate of Group 1 was even 23% slower than Group 2 between 1.75 and 





4.10 Biocompatibility Analysis 
4.10.1 MTT Assay 
In vitro biocompatibility/cytotoxicity of drug-treated sutures was determined using HaCat 
cells (Figure 46). According to the direct method, cells were initially seeded at a density of 5 
x 103 cells/mL per well. Formulation groups and control groups were incubated for 24, 48 
and 72 h in the presence of drug-treated or untreated sutures. Control cells were treated with 
media only. Purple formazan crystals were observed on HaCat cells after adding MTT (Figure 
47). During the experiment, it was interesting to observe that sutures with drug turned purple 
after contact with MTT solution. Whereas, sutures without drug stayed white (Figure 48). For 
that reason, suture alone without cells were also tested to ensure that the suture itself did not 
contribute to the MTT results. Standard curves at 24, 48 and 72 h were generated by 
measuring absorbance at cell numbers of 5 x 103, 10 x 103, 20 x 103, 40 x 103, 80 x 103 
cells/mL (Figure 49).  
Group 1 (F1, F2, F3) were drug-treated polymer (PCL/PEG/chitosan/keratin) sutures, 
embedded with 5, 15, 30 wt% diclofenac potassium, respectively. Group 2 (F4, F5, F6) were 
drug-treated polymer (PCL/PEG/chitosan) sutures, embedded with 5, 15, 30 wt% diclofenac 
potassium, respectively. Group 3 (F7, F8, F9) were drug treated polymer (PCL/PEG/keratin) 
sutures, embedded 5, 15, 30 wt% diclofenac potassium, respectively. Control (C1, C2, C3) 
were polymer sutures containing pure PCL, PCL/PEG400, PCL/PEG400/chitosan/keratin, 
respectively. Cell is HaCat cells only. F3 (Group 1), F5 (Group 2) and F7 (Group 3) exhibited 
a significant decrease on cell proliferation at 24 h (p = 0.0002, p < 0.0001, p = 0.0141, 
respectively). Group 1 had a significant increase on cell proliferation at 48 and 72 h (p = 
0.0001, 0.0002 respectively). Group 2 demonstrated a significant effect on the growth of cell 
number at 48 and 72 h (p = 0.0002, 0.0021 respectively). There was also a significant increase 
of group 3 on the viable cells at 48 and 72 h (p = 0.0039, 0.0002, respectively). 
There was a significant increase (p < 0.05) in cell proliferation associated with drug-treated 
sutures at 48 and 72 h, compared to control samples and cell-only samples (Figure 50, 51, 
52). At 24 h, it is interesting to note that F2, F4 and F6 showed much higher viability of cells 
compared to the control and cell-only samples. However, at 48h, the number of cells in these 




(F1, F2, F3, F4, F5, F6, F7, F8, F9), exhibited similar cell viability with polymer only sutures 
(C1, C2, C3) at 48h (Figure 50, 51, 52). Nevertheless, at 72 h, only group 1 and group 3 with 
formulations F1, F2, F9 showed significantly increased cell viability compared to the control 
group (C1, C2, C3) and cell only (Figure 50, 52). Additionally, F1 achieved the highest cell 
number of 40,000 at 72 h (Figure 50).  
Cell attachment in F1, F2 and F9 was significantly increased with the drug-treated sutures 
compared to the untreated sutures at 72 h. Drug content of these three formulations were 5, 
15 and 30 wt%, respectively. It indicated that Group 3 polymer matrix was able to carry an 
increased drug amount. Whereas, Group 1 polymer matrix performs better cell-substrate 
compatibility with a lower amount of drug. Therefore, in order to further investigate the cell 






Figure 46. HaCat Cells 
Spindle shaped adherent cells that form a cobble stone pattern when confluent. Image taken with x 
microscope, untreated cells.  
 
Figure 47. Purple Formazan Crystals of HaCat Cells  





Figure 48. Colour Changing of Sutures After Adding MTT Solution 
(A) Sutures contained polymer only; (B) Sutures contained polymer blend and drug. 
 
Figure 49. Representative standard curve of MTT assay  







Figure 50. Cell Number for Group 1 via MTT Assay 
Data were collected after 24, 48 and 72 h. Sutures were incubated using the direct method. F1, F2, 
F3 contained PCL, PEG, chitosan, keratin and drug. The drug content of F1, F2 and F3 were 5, 15, 
30% respectively. C1contained PCL only; C2 contained PCL and PEG; C3 contained PCL, PEG, 
chitosan and keratin. Cell represents cell only (i.e. does not contain polymer or drug). Asterisk (*) 
denotes significant difference. * denotes p ≤ 0.05, ** denotes p ≤ 0.01, *** denotes p ≤ 0.001. (n=3, 
data groups were compared with the one-way analysis of variance ANOVA via a post hoc Tukey’s 






Figure 51. Cell Number for Group 2 via MTT Assay 
Data were collected after 24, 48 and 72 h. Sutures were incubated using the direct method. F4, F5, 
F6 contained PCL, PEG, chitosan, keratin and drug, the drug content of F4, F5 and F6 were 5, 15, 
30% respectively. C1contained PCL only; C2 contained PCL and PEG; C3 contained PCL, PEG, 
chitosan and keratin. Cell represents cell only (i.e. does not contain polymer or drug). Asterisk (*) 
denotes significant difference. * denotes p ≤ 0.05, ** denotes p ≤ 0.01, *** denotes p ≤ 0.001. (n=3, 
data groups were compared with the one-way analysis of variance ANOVA via a post hoc Tukey’s 






Figure 52. Cell Number for Group 3 via MTT Assay 
Data were collected after 24, 48 and 72 h. Sutures were incubated using the direct method. F7, F8, 
F9 contained PCL, PEG, chitosan, keratin and drug, the drug content of F7, F8 and F9 were 5, 15, 
30% respectively. C1contained PCL only; C2 contained PCL and PEG; C3 contained PCL, PEG, 
chitosan and keratin. Cell represents cell only (i.e. does not contain polymer or drug). Asterisk (*) 
denotes significant difference. * denotes p ≤ 0.05, ** denotes p ≤ 0.01, *** denotes p ≤ 0.001. (n=3, 
data groups were compared with the one-way analysis of variance ANOVA via a post hoc Tukey’s 





4.10.2 Live/Dead Assay 
Live/ dead assays were conducted on group 1, group 3, control group, and cell-only samples. 
The results were reported at 24, 48 and 72 h with representative images (Figure 53) The 
results for 24, 48, 72 h culturing showed that cell fluorescence was stronger on the surface of 
the sutures which contain drug, possibly indicating that more cells were attached but this 
needs further investigation (Figure 54).  
The live/dead cell ratios were obtained from fluorescence images and counted using Image J 
software. The cells in each sample were treated with Calcein blue for live cell staining of the 
intact cell membrane and propidium iodide (PI) for dead cell staining of the DNA. One-way 
ANOVA analysis showed that at 24 h, suture materials F (13, 27) had an extremely significant 
increase (p < 0.0001) on the live percentage of cells. However, there were no significant 
differences between any of the sutures at 48 and 72 h. At 24 h, control group C2 and C3 
demonstrated relatively higher cell viability at 97% and 99%, respectively. Whereas, the cell-
only sample had the lowest viability at 54%. At 48h, the viability of group 1 and group 3 
samples became stable, and maintained above 90%. When it comes to 72 h, the ratios of live 
cells were 97%, 97%, 98%, 96%, 93%, 96%, 90%, 96%, 92%, 84 % for F1, F2, F3, F7, F8, 
F9, C1, C2, C3, cell only, respectively (Figure 55). Therefore, Group 1 generated relatively 
higher cell viability compared to the other groups. Especially, F3 demonstrated the highest 


































































































Figure 53. Live/Dead Assay with Fluorescence Microscopy. 
 (a) cell fluorescence at 24 h; (b) cell fluorescence at 48 h; (c) cell fluorescence at 72 h. (n=3. Scale 
bar= 200 µm). Green fluorescence represents live cells, red fluorescence indicates dead cells. 
 
 
Figure 54.  Fluorescence of Live/Dead Cells on Sutures 









Figure 55. Ratio of Live/Dead Cells in Response to Different Sutures at 24, 48 and 72h 
Red bars represent the percentage of the dead cells; blue bars represent the percentage of live cells. 
F1, F2, F3 contained PCL, PEG, chitosan, keratin and drug, the drug content of F1, F2 and F3 were 
5, 15, 30% respectively. F7, F8, F9 contained PCL, PEG, chitosan, keratin and drug, the drug content 
of F7, F8 and F9 were 5, 15, 30% respectively. C1 contained PCL only; C2 contained PCL and PEG; 
C3 contained PCL, PEG, chitosan and keratin. Cell represents cell only (i.e. does not contain polymer 





4.10.3 Scratch Assay 
The wound healing assay was used to measure the effect the of polymer/drug on the migratory 
capacity (wound closure rate) of HaCat cells. Pictures obtained through light microscopy on 
the scratched cell monolayer are reported at time 24, 48 and 72 h (Figure 56). Different 
dimensions of the scratch were observed by comparing the polymer sutures and drug-treated 
sutures. The results showed that the combination of polymer and drug (F1, F2, F3) 
significantly increased the gap closure rate compared to polymer only and cell-only samples, 
since some of the samples from formulation F1, F2, F3 were able to close the wound 
completely by 48 h (Figure 56).  
The percentage of migration has been calculated and reported in the graph shown in Figure 
57. A two-way ANOVA analysis showed that time F (1.659, 23.22) had an extremely 
significant effect (p < 0.0001). Whereas the different sample materials F (6, 14) had a very 
significant effect (p = 0.0033). Overall both time and sample materials F (12, 28) significantly 
increased wound closure (p = 0.0038) when compared to the cell-only sample. Before 24 h, 
C1, C2, C3, F1, F2 and cell-only samples demonstrated similar wound closure rates. After 
the 48-h point, cell migration rate largely increased in F1 and F2 samples. For sample F3, it 
exhibited the highest cell migration rate at all times, and it achieved a 99% wound healing at 
48h (Figure 57). Therefore, the F3 material, which contained polymer 
PCL/PEG400/chitosan/keratin as well as 30 wt% diclofenac potassium was the ideal 
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Figure 56. Images of Gap Closure in Wound Healing Assay in Response to Sutures  
Wounds were measured at 0, 24 and 48 h after wound was made. Control cells were treated with 
media only. Suture treated cells were treated through direct contact with sutures (with/without drug) 
Images shown here are representatives. n=6, yellow line outlines the border of the wound. Three 




Figure 57. Percentage of Wound Healing 
F1, F2, F3 contained PCL, PEG, chitosan, keratin and drug, the drug content of F1, F2 and F3 were 
5, 15, 30% respectively. C1 contained PCL only; C2 contained PCL and PEG; C3 contained PCL, 







4.11 Summary of Biocompatibility Tests  
The proliferation assay, viability assay and scratch assay showed that: 
⚫ Group 1, 2, 3 exhibited larger numbers of cells compared to polymer suture samples at 
48 h. However, only Group 1 and Group 3 showed higher cell viability at 72 h. Especially 
F1, which showed the highest cell number of 40,000 cells at 72 h. 
⚫ There was an extremely significant effect (p < 0.0001) on the percentage of viable cells 
at 24 h. However, no difference was exhibited at 48 and 72 h.  
⚫ Group 1(PCL/PEG400/chitosan/keratin/drug) generated relatively higher cell viability at 
72 h compared to other groups. The live cell percentage of F1, F2 and F3 were 97%, 97%, 
98% respectively.  
⚫ F3 demonstrated the highest wound healing rate compared with the other samples. 





Suture implantation is prone to an inflammation response and requires postoperative surgery 
to extract the suture from the patient’s body (Champeau et al. 2017). In order to cope with 
this problem, there is a trend towards developing synthetic biodegradable suture materials 
that combine with anti-inflammatory drugs. Incorporation of the drug with polymer materials 
to produce suture products is important especially when the suture is used for internal organs 
and/or tissues, which also provides the possibility to predict the degradability of the sutures 
in a biological environment (Joseph et al. 2017). For internal targets, direct drug delivery is 
difficult. In some cases, a high drug content of up to 30% is required. However, a higher 
amount of drug leads to lower mechanical properties, as sutures tend to be degraded easily 
(Zhang et al. 2016). Therefore, a robust suture material or material combinations for carrying 
a higher amount of drug are desired. 
In this study, the overall aim was to use the HME technique to generate a surgical suture from 
a novel biomaterial consisting of PCL/PEG400/chitosan/keratin and the drug DP, which has 
excellent mechanical properties, a sustained drug release rate and biocompatibility. To 
complete this aim, the HME technique was optimized, the sutures were characterised 
chemically and physically, and their thermal and mechanical properties were estimated. 
Additionally, DP as the target drug was studied to determine its release profile. Moreover, 
the in vitro biocompatibility of the sutures was assessed.  
The four critical conclusions of this project originate from 1) the optimization of the hot- melt 
extrusion process 2) the characterisation of biopolymer sutures 3) the drug dissolution of drug 
embedded sutures 4) the biological studies of the drug embedded sutures in vitro.  
The conclusions were as follows:  
1) The optimal extrusion temperature for polymer and polymer/drug sutures 
preparation was 63±1 °C. Sutures that contained chitosan/keratin tended to be 
thicker (0.6 ~ 0.9 mm) than sutures fabricated with PCL only and PCL/PEG blend 
(0.4 ~ 0.5 mm). Drug embedded sutures had thickness between 0.8 and 0.9 mm. 
Additionally, higher amounts of PEG400 exhibited a grey colour which appeared on 




2) C3 (PCL/PEG400/chitosan/keratin blend) had the best performance in 
characterisation studies. This blend exhibited a relatively slow and steady 
decomposition rate in the TGA test, and had a lower melting point and glass 
transition temperature in the DSC test. Moreover, in the mechanical test, C3 was 
relatively strong and stiff, with lower elongation at break than pure PCL and 
PCL/PEG blend, but had significantly higher elongation than the other drug 
embedded suture samples.  
3) Group 3 (PCL/PEG/keratin/drug) demonstrated a rapid release profile. Whereas, 
Group 1 (PCL/PEG/chitosan/keratin/drug) and Group 2 (PCL/PEG/chitosan/drug) 
generated a controlled drug release profile. The release rate of Group 1 was even 
slower than Group 2 after 1 h 45 m.  
4) Group 1 (PCL/PEG/chitosan/keratin/drug) showed the highest cell viability at 72 h. 
Furthermore, F3, which had the highest drug content (30 wt%) in Group 1, achieved 
99% wound closure at 48 h. 
5.1 Analysis of Suture Fabrication and 
Characteristics 
5.1.1 Hot- melt Extrusion Parameters  
During HME, process temperature was set at 63±1 °C, since the main polymer carrier selected 
in this study was PCL, which operates optimally at this temperature. PCL has a relatively low 
glass transition temperature (-60 °C) and melting point (60 °C), and it occupied 80% of the 
polymer matrix. In polymer production, the reduction of viscosity is essential, and to achieve 
this, the temperature must be maintained higher (within the range of 30-60 °C) than the glass 
transition temperature (Palazi et al. 2018). The process temperature also needs to be slightly 
higher than the polymer’s melting point to enable material melting and minimize viscosity 
(Palazi et al. 2018).  
PEG400 used in this study, has a melting point at 4 °C and glass transition temperature at -
20 °C. Fibres extruded from these two polymers demonstrated homogenous properties, as 




2013). However, due to the low melting point of PEG400, the colour of the extrudates was 
grey, which can be ascribed to the decomposition of PEG400 (Palazi et al. 2018). To date, 
research on the effect of the decomposition of PEG400 on the efficacy of drug-eluting sutures 
is limited. Therefore, if the change in colour affects drug-eluting properties requiring future 
investigation. 
Chitosan and keratin have a melting temperature of 290 °C and 205 °C, respectively, and 
their glass transition temperature were 203 °C and 155 °C, respectively. Due to the high 
melting points of chitosan and keratin, the extrudates of C3, C4 and C5 were slightly thicker 
than Control groups C1 and C2, owning to the solid granules of chitosan and keratin. 
Comparing extrusion of C4 with C5 under 63±1 °C, C5 required less force to extrude than 
C4, which is attributable to the higher ratio of chitosan/keratin mixture in the polymer content 
of C5. Interestingly, higher amounts of chitosan/keratin in C5 were responsible for the 
extrudates to turn back to white again in colour. This may be due to the lower viscosity 
achieved from the addition of higher amount of chitosan/keratin, which shortened the 
remaining time of materials inside the extruder (Ma et al. 2017). In addition, the higher 
polymer content of chitosan/keratin potentially increased the melting point of the whole blend 
powder, which enhanced the cooling rate of the extrudates and enabled to extrude longer 
fibres (Flores‐Hernandez et al. 2018). 
HME has been widely used as a drug delivery technology and also was chosen to manufacture 
suture products, due to its solvent free and environmentally friendly characteristics, as well 
as its potential to poorly disperse water-soluble drugs in polymers for enhanced delivery 
(Campbell, Craig, and McNally 2010). In the procedure, the API is embedded in a carrier 
system with other functional excipients, which can be melted under the required temperature 
(Patil, Tiwari, and Repka 2016). In addition, this drug can be homogeneously distributed into 
polymer matrix in a molecular level with this method (Liet al. 2013, Champeau et al. 2017). 
In current study, the melting point of DP is about 302-310°C. However, since PCL (55°C) 
and PEG400 (4-8°C) have very low Tm. A heating temperature of 63 ±1 °C was employed 
for melt extrusion process and successfully produced fine extrudates. Other studies also found 
that the HME process temperature can be reduced by mixing drugs with polymers that have 
low Tm, in that not only can the melting point be reduced, the viscosity of polymers can also 




interactions lowering the chemical potential of the drug, and therefore the drug with higher 
Tm can be extruded below its original melting temperature (Li et al. 2014). This concept has 
been demonstrated by the study conducted by Papadimitriou et al. (2012), in which they 
applied Felodipine as a model drug, and PVP/PEG as the drug carrier. The results indicated 
an increase in the miscibility of the PVP-drug system, owing to the presence of PEG which 
acted as plasticizer (Papadimitriou et al. 2012).  
Other processing parameters, such as feeding rate and screw rotating speed were not 
investigated in depth, because the extruder used in this study was not able to control the 
rotating speed. However, other studies have looked at the effects of processing parameters 
with PEG as plasticiser in detail, in particular Barmpalexis et al. (2013) carried out a thorough 
investigation on the effects of the different temperatures, mixing times and rotating speeds 
on the solid dispersions of PVP/PEG/drug mixtures (Barmpalexis et al. 2013). Importantly, 
different room temperatures and compositions of polymer mixtures may alter the specific 
parameters identified in the current project for melt extrusion of drug-eluting sutures. 
Therefore, the parameters used here should be considered as a guideline for future studies 
and it is highly recommended that an exhaustive optimisation must be carried out for each 
new experiment.  
5.1.2 Characterisation of Polymer Sutures 
The FTIR spectra for neat PCL was similar to spectra reported elsewhere, showing 
characteristic peaks around 2943 cm-1, 2866 cm-1, 1721 cm-1, 1238 cm-1 and 1163 cm-1 
corresponding to –C–H asymmetric and symmetric stretching, –C=O stretching of the ester 
carbonyl group and C–O–C asymmetric and symmetric stretching (Elzein et al. 2004, 
Edwards et al. 2015).There was a slightly rounder peak in PCL/PEG blend (1161 cm−1), 
which could be ascribed to the C-O and C-C stretching in the amorphous phase(Yu et al. 
2014).  
For PCL/PEG400 blend, PCL provided free carbonyl groups that acted as potential proton 
receptors, and free hydroxyl groups in PEG400 that acted as potential proton donors. 
Hydrogen bond interactions may occur in PCL-PEG400 blend (Zehnder et al. 2016, Elzein 
et al. 2004). Additionally, there was a peak at 3441 cm-1 in the PCL/PEG blend, which also 




no shifts or new peaks visible in PCL-PEG400 blend (Figure 34, C2), probably due to the 
intermolecular interactions (Yu et al. 2014). 
These spectral characteristics did not change with the addition of chitosan and keratin (Figure 
34). Generally, Fourier Transform Infrared (FTIR) spectral analysis is used to investigate the 
chemical structure and the different types of bonding within a composite through recording 
the unique vibrational characteristics of specific molecules in response to a certain length of 
IR waveband (Steele 1971). However, FTIR was not able to detect the difference between 
PCL/PEG400 blend (C2) and PCL/PEG400/chitosan/keratin blend (C3, C4, C5). Possibly 
because the chitosan/keratin blend in the polymer matrix was too low (1, 2, 3 wt%, 
respectively) to be detected by FTIR. However, the peaks around 1720 cm-1 showed different 
intensities in chitosan-keratin contained fibres. The control group that contains the highest 
PEG concentration (C3, PEG=19 w/w) showed a higher intensity compared to the other two 
control groups with lower PEG concentration, corresponding to the higher amount of –C=O 
bonds (Tran and Mututuvari 2015). The peak at 1106 cm-1 in chitosan-keratin containing 
samples showed a higher intensity with the increase in the concentration of the 
chitosan/keratin blend. The slightly shifted and wider peak at 1160 cm-1 in the spectrum of 
C5 indicated the miscibility of the polymers and the presence of the hydrogen bonding 
interaction (Liu et al. 2006). 
The overlay FTIR spectra of all the samples including control group C1, C2, C3, C4, C5 and 
chitosan, keratin alone as well as the chitosan/ keratin blend may be found in Figure 34. For 
the chitosan and keratin 50:50 blend, the bands appeared at 1700-1600 cm-1 and 1550 cm-1, 
representing amide C=O stretch (amide I) and C-N stretch (amide II) vibrations, respectively 
(Tran and Mututuvari 2015). The N-H stretch vibration (amide A) was exhibited at the 3280 
cm-1 band. A band at 1300-1200 cm-1 can be attributed to the combination of the N-H 
bending between chitosan and keratin, as well as the C-N stretch vibrations (amide III) (Tran 
and Mututuvari 2015).  
The varying structures of polymer networks and mechanical characteristics of the five control 
groups were also evident in the thermal behaviour and tensile testing. TGA showed that the 
5 control groups all had a one-step degradation. Pure PCL started to degrade through ester 
pyrolysis and unzipping depolymerization reactions, resulting in the rupture of its chains 
(Ghorbani et al. 2016). Consistent with literature findings, PCL/chitosan blend was found to 




(Ghorbani et al. 2016). Additionally, another study compared pure PCL with PCL/vital wheat 
gluten mixture showed that neat PCL had higher thermal stability (Mohamed et al. 2008). 
Therefore, PCL itself already has a very high degradation temperature. So, when adding 
PEG400 into PCL (C2), the degradation started at a much lower temperature (326 °C). 
Nevertheless, the thermal stability of fibre samples was maintained the same as neat PCL, by 
adding the chitosan/keratin blend by 4 wt% into PCL/PEG400 blend (C5). For example, the 
degradation temperature of C5 (PCL: PEG400: chitosan/keratin= 80:16:4 w/w) was 378 °C, 
and C1 (pure PCL) started to degrade at 375 °C.  
In this study, DSC measurements used the second heating and cooling DSC cycles, in order 
to eliminate the thermal history of PCL (Mohamed et al. 2008). DSC data was used to 
determine the degree of miscibility of polymer composites, the degree of intermolecular 
interactions between polymers, and the degree of crystallization. The presence of the single 
Tg and single Tm for all the composites indicated the miscibility or interaction of molecules 
(Mohamed et al. 2008). Since PEG400 is a plasticizer, adding PEG400 in the PCL reduced 
the melting point and glass transition temperature. Moreover, the addition of chitosan/keratin 
blend decreased Tg even further, which can be ascribed to the formation of intermolecular 
hydrogen bonds between the PCL/PEG and chitosan/keratin in the amorphous phase, leading 
to a suppression of the crystallization of PCL/PEG (Ghorbani et al. 2016). 
Tensile testing aptly reflected the mechanical properties of the fibres with five different 
formulations. The pure PCL (C1) has relatively low stiffness, but the addition of PEG400 
(C2) (acts as plasticiser) was intended to improve ductility (Barmpalexis et al. 2013). 
However, the mixture of PCL/PEG400 had lower elongation at break (110%) than C1 
(123%). This might be due to the blending ratio of PCL with PEG400, which requires future 
work. Chitosan has limitations in that it has very low tensile strength, which does not meet 
the requirements for many biomedical applications. For instance, in tissue engineering, 
chitosan alone cannot be used to mimic articular cartilage, since the tensile strength of a 
cartilage required is to be around 27 MP, whereas the tensile strength of chitosan is only 5-7 
MPa when wet (Cheng et al. 2003). Keratin alone is also mechanically weak and is not able 
to maintain its structural integrity (Thompson et al. 2016). However, the composite of 
PCL/PEG400 (C2) showed lower stiffness compared to samples contained chitosan/keratin 
(C3, C4, C5). Adding chitosan/keratin (50: 50 w/w) (having high melting points) increased 




The elastic modulus was improved by 20% in samples that contained 1% chitosan/keratin 
(C3). The addition of chitosan/keratin also had a dramatic impact on the elongation of fibres. 
The elongation at break was reduced concomitantly with the addition of chitosan and keratin 
(67%, 21%, 20% for C3, C4, C5 respectively), potentially due to the formation of lumps on 
the fibre surfaces. 
In summary, the analysis of the physical and mechanical characteristics of polymer sutures 
successfully identified the molecular interaction and hydrogen bonding (using FTIR) in the 
polymer matrix, as well as the plasticity effect contributed by PEG400. It appears that the 
control group C3 (PCL: PEG400: chitosan/keratin= 80:19:1 w/w) has the best potential for 
suture applications because it showed the miscibility of polymers, and had relatively stable 
thermal behaviour up to 348 °C. Most importantly, it formed strong and stiff fibres with 
proper elongation, which would be an ideal suture for soft tissue applications, such as 
muscles, tendons, ligaments and fascia (Guo and Ma 2014). 
5.1.3 Polymer Composites as Drug Carriers 
In this study, the drug content used for the polymer matrix was 5, 15 and 30 wt%, as this 
successfully allowed the extrusion of fine fibres at 63±1 °C. Even though there are many 
advantages of using the HME technique to produce drugs, the drug load needs careful 
consideration. Under most circumstances, the drug load is limited to 30% of the whole dosage 
(Claeys et al. 2015) since high drug load or the drug release would be uncontrollable with 
lower proportion of polymer incorporated in the formulation (Palazi et al. 2018). However, 
there are ways to optimize the drug load amount. For example, by using PCL (synthetic 
polymer) which has a relatively low melting point of 59-64°C, combining it with polymer 
PEG400 (which acts as a plasticizer) and chitosan/keratin (have high melting points), it will 
reduce manufacturing temperature to create a safe environment to produce fibres that contain 
drug DP (Barmpalexis et al. 2013).  
According to previous studies, PCL is compatible with a wide range of pharmaceutical 
ingredients, which allows drug to distribute uniformly throughout the polymer matrix and to 
modify its physical, chemical and mechanical properties (Dash and Konkimalla 2012a). In 
this study, successful concentrations of chitosan/keratin loaded into PCL/PEG400 that could 




30%. Higher loading concentration of DP (≥ 30%) caused the cessation of any material 
being extruded from the nozzle. Our results were similar to those found by Vithani et al. 
(2014) who applied the hot melt extrusion method to produce lipid matrices which contain 
drug DP to achieve controlled release. They designed a drug content that varied from 30 to 
40%. The extrudates produced from extruder were fine strands with 1 mm thickness. Our 
product produced fibres of a similar size of about 1mm, and also observed that a higher drug 
content led to low viscosity and improved flow behaviour under the hot melt extrusion 
process (Vithani et al. 2014). 
5.2 Analysis of Drug Dissolution with Products 
Produced by Solid Dispersion Technique 
5.2.1 Solid Dispersion  
Over several decades, hot- melt extrusion has been used as a novel technology for 
manufacturing solid dispersions of active pharmaceutical ingredients into polymer matrices 
(Maniruzzaman et al. 2013). The high shear mixing of the molten mass allows the drug and 
polymers to be mixed at the molecular level to achieve drug-polymer interactions (Sarode et 
al. 2013). Solid dispersion form has already been reported to have the ability to control and 
extend the drug releasing time, resulting in improved bioavailability (Lakshman et al. 2008, 
Maniruzzaman, Rana, et al. 2013).  
In this study, PCL, PEG400, chitosan, keratin and drug DP were melt-extruded into fibre 
form. The drug was dispersed in the polymer matrix with reduced particle size and 
agglomeration, forming an amorphous state to increase the available surface area and 
therefore, enhance the dissolution of the drug (Craig 2002, Leuner and Dressman 2000, 
Vasconcelos, Sarmento, and Costa 2007).There are two known, basic pathways for drug 
release from a polymer matrix, including drug diffusion and matrix degradation (Song, 
Labhasetwar, and Levy 1997). For example, PCL has good characteristics in both drug 
diffusion and matrix degradation, as it has been shown that it can provide sustained drug 
release due to its high permeability to many drugs (Dordunoo et al. 1997). The solid 




matrix, allowing for tailoring the degradation kinetics and drug release rates (Azimi et al. 
2014).  
PEG400 is a water-soluble polymer, which is widely used as a drug carrier in the preparation 
of solid dispersion systems was thus selected for this study. Previous studies employed 
paclitaxel as a drug carrier, but this has too poor a water solubility to be the model drug. The 
drug release rate between blends prepared by solid dispersion and blends prepared by physical 
mixtures showed that the dispersion of paclitaxel in PEG can effectively modify drug release 
from PCL films (Shen et al. 2013). Formulation groups containing varying proportions of 
polymers (G1, G2 and G3) all observed drug release within 15 minutes (Figure 42-44), which 
can be ascribed to the brilliant effect of PEG400 on improving drug solubility. 
These findings demonstrated that the solid dispersion significantly improved the solubility of 
drug inside the polymer matrix. However, in order to obtain the optimal formulation for drug 
release, the dissolution behaviour was also investigated.  
5.2.2 Dissolution Behaviour  
In the current project, drug content of 5, 15 and 30 wt% were blended into polymer 
composites of PCL/PEG400/chitosan/keratin, PCL/PEG400/chitosan and 
PCL/PEG400/keratin, forming formulation F1 to F9. According to the different polymer 
compounds, samples were classified into 3 groups. When the drug contents were at 5 wt%, 
the drug dissolved within the polymer medium first, followed by diffusing to the surface of 
the fibres (F1, F4, F7). Slightly higher drug loadings (10 wt%) allowed for the formation of 
cavities near the device surface during drug delivery. Fluid from the external environment 
may fill these cavities, which provides pathways for the remaining material and drug to be 
released from the device (F2, F5, F8). When the drug content reached 30 wt%, the formation 
of the cavities is enough to build a continuous channel to the surface of the device allowing 
drug diffusion through those channels (F3, F6, F9) (Douglas et al. 2010). Figure 45 
demonstrates the release profiles of the F3, F6 and F9, with highest drug content (30 wt%). 
F9 (PCL/PEG/keratin/drug) exhibited a rapid release within the 1.75h, followed by a 
controlled release. Moreover, F3 (PCL/PEG/chitosan/keratin/drug) and F6 
(PCL/PEG/chitosan/drug) showed a sustained drug release, but F3 showed more stable 




Typical drug delivery systems require three factors. The correct matrix structure to hold the 
drug delivery system together but not contribute to the drug diffusion during drug delivery. 
The aqueous solution, which is whatever aqueous material is that is coming inside the matrix 
structure from the external environment. Thirdly, the drug, which is diffuses from the inner 
matrix into the external environment (Douglas et al. 2010). Once inside the polymer matrix, 
the drug dissolution rate depends on the solubility and permeability of the drug within the 
polymer, as well as to the biodegradability of the polymer (Douglas et al. 2010). Once inside 
the polymer matrix, the drug dissolution rate depends on the solubility and permeability of 
the drug within the polymer, as well as to the biodegradability of the polymer (Douglas et al. 
2010). For instance, hydrophilic active ingredients have better solubility in a hydrophilic 
polymer. Similarly, lipophilic active ingredients reveal better solubility in a hydrophobic 
polymer. Thus, adding hydrophilic/phobic polymers can effectively improve the solubility of 
a drug in an incompatible polymer (Fini et al. 1996).  
In drug delivery studies, PCL showed a slow degradation rate attributed to its high 
crystallinity and hydrophobicity (Sahoo et al. 2010). However, because PEG400, a liquid 
polymer, was added in all the formulations and it has very short degradation time of 72 h 
(Browning et al. 2014). Therefore, besides the weight loss that was expected from the drug 
release, the weight loss observed in the suture can also be attributed to the addition of 
PEG400. This was confirmed by a previous study which investigated the effect that PEG has 
on the release profile of the drug diclofenac sodium after manufacturing with hot melt 
extrusion method. Researchers found that the weight loss of PLA/ PEG blends was mainly 
due to the dissolution of PEG (Chen et al. 2016). Another study reported that PEG-based 
fibres manufactured by hot melt extrusion method have greater release rate with the increased 
PEG content. Up to 60% of PEG was released within 24 h (Cheng, Lei, and Guo 2010).  
Despite the fast degradation of PEG400 and its effect on the integrity of the fibres, the cavities 
formed by the release of PEG have the potential to improve drug release from the matrix 
(Cheng, Lei, and Guo 2010). Group G1 (including F1, F2, F3, contains 
PCL/PEG/chitosan/keratin) exhibited an increased release rate after 1.75 h. And the increase 
of dissolution speed was observed between 1.75 and 3.75 h for group G2 (includes F4, F5, 
F6, contains PCL/PEG/chitosan). For the highest drug content group G3 (includes F7, F8, 
F9, contains PCL/PEG/kratin), relatively fast release speed was demonstrated at time 




Zhang et al. (2016) compared the drug release from pure PCL with the PCL/PEG blends, 
which prepared by hot-melt extrusion method. They found that the pure PCL matrix released 
only 4% of drug in 7 days. In contrast, more than 80% of drug was released in 72 h for the 
polymer blends with 30% of hydrophilic components (Zhang et al. 2016). However, the 
current study did not look at the PEG degradation kinetics in depth, which requires future 
work.   
In summary, PCL and PEG were used to serve as the main drug carriers, while chitosan and 
keratin served as additives. Generally, all the samples demonstrated slow drug release 
patterns and the addition of chitosan/keratin or chitosan, keratin alone significantly affect 
drug release rate. In the group 4 (F3, F6, F9) which contained highest drug content (30 wt%), 
F9 achieved sustained release after 3.75 h, but F3 exhibited slower dissolution behaviour in 
the whole experimental period (Figure 45). In some cases, when the acceleration of drug 
release rate is required, higher PEG content can be considered (Cheng, Lei, and Guo 2010). 
Since in the formulation of this study, when drug content up to 30% was employed, 19% of 
PEG could cause the drug to start to release within 0.25 h.  
5.3 Analysis of Biocompatibility of the Sutures 
An ideal material for a drug delivery matrix or implantable device should not release toxic 
products or trigger adverse reactions (Grehan et al. 2014). When using novel polymer blends 
with drugs, one must always be aware of potential unwanted side effects. Therefore, an 
important step in the development of a suture product is the assessment of any safety risk. Of 
particular interest are parameters of cytotoxicity and biocompatibility of the sutures. PCL, 
PEG and PCL-PEG products have been approved by the Food and Drug Administration 
(Grossen et al. 2017). However, chitosan and keratin have not been approved by the FDA for 
drug delivery, and the addition of drugs has often unknown side effects on human cells.  
To investigate the biocompatibility of the suture products, in vitro toxicity testing is used. 
This test aims to investigate cytotoxicity, cytocompatibility, cell proliferation, cell adhesion 
and cell migration (Lendlein et al. 2010). Unfortunately, a single method to cover all the 
general toxicity in humans is not yet known. As such, several in vitro tests along with 




extruded sutures (Pizzoferrato et al. 1994, Kirkpatrick et al. 1998, Hanks, Wataha, and Sun 
1996).  
5.3.1 Effect of Drug-Eluting Sutures on Cell Proliferation 
Suture biocompatibility tests are commonly performed done on tissues and cells in the lab as 
a starting point. For example, skin is composed of three main types of cells, including 
keratinocytes, melanocytes, and fibroblasts (Ji, Li, and Chen 2008). Human immortalized 
keratinocyte (HaCaT) cells are model cell lines which play an important role in epidermal 
tissue regeneration (Muniandy et al. 2018). HatCaT cells may turn into human keratinocytes 
with the same properties of basal epidermal keratinocytes (Meineke et al. 2004, Maas-
Szabowski, Stärker, and Fusenig 2003).  
HaCat cells were chosen for this study because of their availability, and their immortalized 
nature which allows them to be used for an extended amount of time compared to primary 
cell lines. In addition, HaCat cells grew faster than human dermal fibroblasts, such as Nhdf, 
which are located in the dermis of skin (Muniandy et al. 2018). In the current project, HaCat 
cells became confluent within one week during the cell culture process.  
It was possible to conduct direct contact for MTT assay owing to the insoluble nature of the 
main polymer, PCL (Grehan et al. 2014). Three groups of drug-treated sutures were 
immersed in the solution containing HaCat cells. Amongst these three groups, Group 1 which 
contained chitosan/keratin (1:1 w/w) demonstrated a significant increase on cell numbers at 
72 h (p = 0.0002). The result is consistent with the former findings when chitosan: keratin 
was 1: 1 w/w, the cell viability was significantly increased at day 3, compared to the other 
two ratios (chitosan: keratin= 1: 0.5 and 1:0.25 w/w, respectively) (Flores‐Hernandez et al. 
2018).  
However, experimental testing revealed that the different drug content combined with the 
polymer types promoted cell growth. For instance, in group 1 (containing 
PCL/PEG/chitosan/keratin), the lowest drug content (5 wt%) showed highest number of cells 
(~ 40,000) in the entire treated samples at day 3. In contrast, group 3 (containing PCL/PEG/ 




HaCaT cells tend to grow on the hydrophilic surfaces as they are mainly attached to carbonyl 
and carboxyl groups (Lehocký et al. 2009, Lehocký et al. 2006, Peschel et al. 2008). 
Therefore, polar surface entities play an important role in cell growth factors. In addition, 
hydrogen bonding and van der Waals forces also contribute to improved cell attachment, and 
this reinforcement provides a bridge between samples and cells (Paleos, Tsiourvas, and 
Sideratou 2004) which may promote cell adhesion and cell proliferation (García et al. 2010).  
In current study, the total formulation amount was consistent, and PCL content was fixed (80 
wt%), which means that lower drug content was indicative of the higher amount of PEG400 
in the formulations, which can be used to explain the highest cell number (~ 40,000) observed 
in F1 at 72 h. The relatively high cell number that was observed in F9 at 72 h was mainly 
attributable to varying surface properties of matrix after melt extruding with different drug 
content (Grehan et al. 2014), since melt extrusion created a product with a hydrophobic 
surface. Higher drug content with keratin may have modified the surface properties of fibres 
and thus improved cell attachment and proliferation as well (Edwards et al. 2015). 
In summary, group 1 and group 3 demonstrated better performance than group 2 in the cell 
proliferation study. Therefore, Group 1 (F1, F2, F3) and Group 3 (F7, F8, F9) were selected 
for the investigation of HaCat cell viability. 
5.3.2 Effect of Drug-Eluting Sutures on Cell Viability 
Hacat cell viability of the melt-extruded fibres was analysed using the live/dead assay. 
Fluorescence staining was employed to visualise the cells that were under direct contact with 
6 formulations respectively. At 24 h, suture materials F (13, 27) had an extremely significant 
increase (p < 0.0001) on the live percentage of cells. However, at 48 and 72 h, there were no 
significant differences between cell only, control group and drug embedded samples for HaCaT cell 
lines (p > 0.5). This indicated that the fibres containing of drug is not only non-toxic to the 
HaCat cells, but may also enhance the cell proliferation, which in turn may aid wound healing  
Polymer sutures (C1, C2, C3) also showed high cell viability at 72 h, probably due to the 
main polymer content, PCL, which occupied 80 wt% of each formulation. PCL was also used 
as a main polymer by a previous study which incorporated PCL with milk protein by melt 
extrusion method. The biological testing showed that the materials had no cytotoxicity 




ratio of 1: 1 w/w, which is similar as this study, the results showing that the combination of 
chitosan/keratin significantly improved cell viability percentage (Flores‐Hernandez et al. 
2018).  
In summary, PCL/PEG400/chitosan/keratin (Group 1) and PCL/PEG400/keratin (Group 3) 
were investigated for their cytotoxicity with live/dead assay. Both groups showed very high 
cell viability at 48 and 72 h. Group 1 demonstrated slightly higher percentage of viable cells 
compared to group 3 at 72 h. In light of the literature findings, many studies have reported 
that PCL is non-toxic (Grossen et al. 2017, Ghosh et al. 2010). Additionally, hydrophilic 
property of PEG400 is preferable for the attachment of HaCat cells (Lehocký et al. 2009). 
Moreover, the biocompatibility of chitosan and keratin is well studied, suggesting their 
potential for enhancing cell proliferation (Flores‐Hernandez et al. 2018). Following these 
findings, the scratch assay was conducted to further investigate the migration speed of HaCats 
under the effect of drug embedded polymer sutures.  
5.3.3 Effect of Drug-Eluting Sutures on Cell Migration 
Cells migration is essential for many physiological processes, including tissue regeneration 
and wound healing (Balekar et al. 2012). As mentioned above, the scratch assay was carried 
on via direct method in order to study the possibility of interaction of the polymers and drug 
with the wound healing process. Following this rationale, a scratch was created in the 
keratinocyte monolayer, cell to cell contacts thus were broken down, resulting in the increase 
of the number of growth factors and cytokines at the edge of the wound (Liang, Park, and 
Guan 2007). Afterwards, keratinocytes (HaCats) started to proliferate and migrate to the 
wound site, which is the second phase of wound healing (Gurtner et al. 2008).  
The cell only sample indicated the natural rate of migration of the cells, without the influence 
of the polymer materials and drug. And the control group represents the polymer only sutures. 
The entire treated group 1 even with the lowest concentration showed some significant 
increase in migration rate compared to cell only and control group. 
Interestingly, the results showed that the suture contained 30 wt% of drug (F3) enhanced cell 
proliferation and migration ability, and also improved the capability of HaCat cells to close 




2010). It achieved 99% wound closure at 48 h. Therefore, the scratch assay further confirmed 
that F3 is the optimal formulation with the ideal biocompatibility. 
5.4 Comparison of Suture Sample with Commercial 
Product 
The comparation of the best performing suture sample F3 (PCL/PEG400/chitosan-keratin= 
80/19/1 w/w), with commercially available suture Monocryl (poliglecaprone 25) which 
consists of both PGA and PCL (Bezwada et al. 1995), is shown in table 20. Suture F3 and 
Monocryl both demonstrated low tissue reaction. However, F3 exhibited much lower 
mechanical properties then Monocryl, which can be ascribed to the high drug loading rate. 
Interestingly, the elongation of F3 is much higher than commercial product Monocryl. 
Therefore, even though the tensile strength of the formulation suture in this study is lower 
than commercial product Monocryl, the drug-embedded properties and the high elongation 
characteristics carried by the suture F3 has more promising applications in clincal settings.   
Table 20. The Comparison of Sample F3 with Commercial Product of Monocryl 
Properties  F3 Monocryl 
Drug loading (wt%) 30 0 
Diameter (mm) 0.6 0.38 
Elongation at break (%) 66.0 39 
Failure load (N) 5.5 71.82 
Tissue reaction Low Low 
 
5.5 Critical Analysis of Methodology and 
Limitations 
The in vitro skin model was used for cytotoxicity analysis of the biomaterials and drug as a 
whole. In vitro models are predictable, they are easy to build and maintain, as well as a wide 
range of results can be provided. However, some limitations within in vitro models can inhibit 




independency of the cells in each well, when cells were plated at the same time and originated 
from the same cell culture flask. Due to the correlation among the wells on each plate, which 
would consider the data as pseudoreplicates (Ranstam 2012). Although in this study, even 
though the cells came from the same origin, the flasks were treated individually. 
The reason that MTT assay was selected to investigate cell number on the drug embedded 
sutures was due to this assay being able to detect live cells via production of formazan crystals 
accurately. The formazan crystals are produced by mitochondrial reductases, which does not 
exist in dead cells. Even though this assay is relatively reliable, its limitations need to be 
considered before interpreting the results. The most significant limitation is that if the 
materials or active ingredients used in the experiment alter the mitochondrial signalling 
pathways in the cells, it may lead to the change of the amount of formazan crystals formation, 
which can cause the inaccurate results due to the false number of cells (Van Meerloo, 
Kaspers, and Cloos 2011). This could be why F2, F4 and F6 showed much higher cell number 
in the MTT assay at 24 h, however the incubation of the sutures alone without cells negated 
that possibility. 
The wound healing assay was easy to conduct and inexpensive, and the results were rapidly 
produced. During this experiment, cells were moving in one direction to close the wound, 
which makes the results relatively predictable. Additionally, the velocity of the movement of 
the cells may be determined by recording the morphology of cells in real-time. However, one 
limitation is that the scratch tool used and the well sizes used may impact cell migration 
(Staton, Reed, and Brown 2009). However, this limitation was controlled for by using the 
same method across all different groups. Furthermore, because the scratches were made by 
hands, the size, shape, and the gap width between scratches can be variable every time once 
a new experiment starts. Similarly, this limitation was controlled for by having only one 
researcher create the scratches.  
The limitation of the live/dead assay is that the calcein blue reacts to live cells and produces 
green fluorescent products that are trapped inside the cells. Propidium iodide can penetrate 
dead cell membranes and bind with nucleic acids to generate red fluorescence products. Live 
cells are assumed to be equipped with completely intact cell membranes, and thus PI will not 
react to them at all (Pollack and Ciancio 1990). If the cell membranes of live cells become 
accessible to PI dye, the dead cell number, therefore, will not be accurately calculated. 




small enough that studies do not encounter issues, so this may be a problem for studies that 
manipulate the nature of cell walls rather than studies that test cell survivability (Hajem et al. 
2013).  
The limitations of this study are offset by having multiple assays that may cross reference 
each other. For instance, the combination of MTT and live/dead assay, not only could live 
cells number be calculated, the dead cell percentage could also be obtained. Furthermore, the 
combination of wound healing assay and the MTT assay could detect the drug effect on cell 
migration rate. 
5.6 Future Directions 
The results from this study can contribute a wealth of new knowledge to the field of 
bioengineering, particularly for surgical suture application – for example this suture type has 
great potential for wound healing, as was demonstrated by the increase of cell survival when 
the suture blend with 30% drug was used. This study also encourages the recruitment of 
chitosan/keratin as part of the suture material. However, there is still much left to explore. 
Specifically, the complete drug release time and the suture degradation time are unknown, 
and indeed PEG400 dissolution profile is not investigated. If PEG dissolution and suture 
degradation times (and drug release) are satisfactory, then one may try in vivo test to observe 
wound healing inside an animal model, this, more closely approximating the behaviour of the 
suture in a human body. Therefore, future studies should examine the PEG release pattern 
within an extrudate, and the time that a suture needs to degrade as well as the embedded drug 
needs to completely release, in order to back up and extend the findings of this current study.   
Other research has also demonstrated the antimicrobial activity of chitosan and the anti-
inflammation effect of diclofenac potassium (Catanzano et al. 2014, Kim et al. 2017, Leaper 
et al. 2017, Onesti, Carella, and Scuderi 2018). This effect was not investigated here because 
it was a study designed to see if the incorporation of PEG400/chitosan/keratin into PCL could 
improve suture performance and if the drug release profiles differ in drug/polymer ratios. 
Moreover, this study was only designed to investigate immediate cell effects, leaving future 
work to elucidate the method of action of the sutures over time. Therefore, future studies 
should seek to determine if the chitosan-containing sutures show any antimicrobial effect, 




embedded sutures, using methods such as agar diffusion test (Reinbold et al. 2017), and in 
vivo experiments on mice (Catanzano et al. 2014).  
5.7 Conclusion 
In summary, this study sought to investigate and standardise a drug-eluting anti-inflammatory 
suture fabricated by the hot- melt extrusion method. This suture contained biomaterials 
including PCL, PEG400, chitosan and keratin, as well as diclofenac potassium. PCL was 
found to perform better if blended with other materials in powder form first, and then the 
addition of the aqueous polymer of PEG400, to avoid the formation of bulk lumps. Various 
formulations with and without drug could be extruded with fine fibres at 63±1 °C, longer 
fibres could be obtained with higher chitosan/keratin content, probably due to their high 
melting points.  
All the extrudates showed a homogenous distribution of filler, which confirmed findings from 
FTIR and DSC studies. Hydrogen bond interactions existed in all the PEG400 containing 
samples, which is the main power allowing polymers to be mixed in the molecular level. 
From the TGA study, it was observed that the addition of chitosan/keratin reduced and 
stabilised decomposition rate. DSC results showed that all the samples presented a single Tg, 
indicating the miscibility or interaction of molecules. Moreover, the presence of PEG400 in 
the extrudates reduced the melting points of the polymer composite, accounting for the low 
melting point and glass transition temperature of PEG400. Mechanical testing indicated that 
the suture containing 1% chitosan/keratin blend had relatively good mechanical properties. 
The product was strong and stiff, with proper elongation, required a slightly higher strength 
to break.  
Drug dissolution testing demonstrated that the addition of chitosan in the polymer-drug 
composites can tune the drug release profile in a controlled manner. Chitosan/keratin blend 
improved drug dissolution stability. When it comes to the biocompatibility of sutures, no 
sample showed cytotoxicity to human keratinocytes. Additionally, the suture which contained 
the polymer blend (PCL/PEG400/chitosan/keratin) with 30% of drug content exhibited the 
highest wound healing rate achieving 99% wound closure at 48 h.   
Overall, the strategy used in this study has great potential since the hot melt extrusion method 




The product developed in this study would be the most suitable for use as a suture in the 
clinical field. Nevertheless, in vivo study should be further applied to the future work to back 
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